<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006656</article-id><article-id pub-id-type="pmc">PMC11861799</article-id><article-id pub-id-type="doi">10.3390/vaccines13020109</article-id><article-id pub-id-type="publisher-id">vaccines-13-00109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of a Recombinase-Mediated Cassette Exchange System for Gene Knockout and Expression of Non-Native Gene Sequences in <italic toggle="yes">Rickettsia</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6814-5669</contrib-id><name><surname>Cull</surname><given-names>Benjamin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vaccines-13-00109" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00109" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Burkhardt</surname><given-names>Nicole Y.</given-names></name><xref rid="af1-vaccines-13-00109" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Khoo</surname><given-names>Benedict S.</given-names></name><xref rid="af2-vaccines-13-00109" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8738-112X</contrib-id><name><surname>Oliver</surname><given-names>Jonathan D.</given-names></name><xref rid="af2-vaccines-13-00109" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xin-Ru</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-13-00109" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00109" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-0833-4032</contrib-id><name><surname>Price</surname><given-names>Lisa D.</given-names></name><xref rid="af1-vaccines-13-00109" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3881-737X</contrib-id><name><surname>Khanipov</surname><given-names>Kamil</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-vaccines-13-00109" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Rong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af4-vaccines-13-00109" ref-type="aff">4</xref><xref rid="af5-vaccines-13-00109" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Munderloh</surname><given-names>Ulrike G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vaccines-13-00109" ref-type="aff">1</xref></contrib></contrib-group><aff id="af1-vaccines-13-00109"><label>1</label>Department of Entomology, College of Food, Agricultural and Natural Resource Sciences, University of Minnesota, St. Paul, MN 55108, USA; <email>burkh032@umn.edu</email> (N.Y.B.); <email>wangxin@upstate.edu</email> (X.-R.W.); <email>pric0129@umn.edu</email> (L.D.P.); <email>munde001@umn.edu</email> (U.G.M.)</aff><aff id="af2-vaccines-13-00109"><label>2</label>Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA; <email>khoo0011@umn.edu</email> (B.S.K.); <email>joliver@umn.edu</email> (J.D.O.)</aff><aff id="af3-vaccines-13-00109"><label>3</label>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA; <email>kakhanip@utmb.edu</email></aff><aff id="af4-vaccines-13-00109"><label>4</label>Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; <email>rofang@utmb.edu</email></aff><aff id="af5-vaccines-13-00109"><label>5</label>Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA</aff><author-notes><corresp id="c1-vaccines-13-00109"><label>*</label>Correspondence: <email>cull0122@umn.edu</email></corresp><fn id="fn1-vaccines-13-00109"><label>&#x02020;</label><p>Current address: Department of Microbiology and Immunology, Upstate Medical University, Syracuse, NY 13210, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>109</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: Incidence of vector-borne diseases, including rickettsioses and anaplasmosis, has been increasing in many parts of the world. The obligate intracellular nature of rickettsial pathogens has hindered the development of robust genetic tools for the study of gene function and the identification of therapeutic targets. Transposon mutagenesis has contributed to recent progress in the identification of virulence factors in this important group of pathogens. Methods: Combining the efficiency of the himar1 transposon method with a recombinase-mediated system, we aimed to develop a genetic tool enabling the exchange of the transposon with a cassette encoding non-native sequences. Results: This approach was used in <italic toggle="yes">Rickettsia parkeri</italic> to insert a himar1 transposon encoding fluorescent protein and antibiotic resistance genes for visualization and selection, flanked by mismatched <italic toggle="yes">loxP</italic> sites to enable subsequent recombinase-mediated cassette exchange (RMCE). RMCE mediated by a plasmid-encoded Cre recombinase was then employed to replace the transposon with a different cassette containing alternate fluorescent and selection markers and epitopes of <italic toggle="yes">Anaplasma phagocytophilum</italic> antigens. The resulting genetically modified <italic toggle="yes">R. parkeri</italic> was trialed as a live-attenuated vaccine against spotted fever rickettsiosis and anaplasmosis in mice. Conclusions: The use of this system provides a well-established and relatively efficient way of inserting non-native sequences into the rickettsial genome, with applications for the study of gene function and vaccine development.</p></abstract><kwd-group><kwd><italic toggle="yes">Rickettsia</italic></kwd><kwd><italic toggle="yes">Anaplasma</italic></kwd><kwd>live-attenuated vaccine</kwd><kwd>transposon mutagenesis</kwd><kwd>genetic tools</kwd></kwd-group><funding-group><award-group><funding-source>Department of Defense U.S. Army Medical Research and Materiel Command</funding-source><award-id>W81XWH-18-1-0319</award-id></award-group><funding-statement>Generous funding in support of this research was provided by the Department of Defense U.S. Army Medical Research and Materiel Command, grant number W81XWH-18-1-0319.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00109"><title>1. Introduction</title><p>The incidence of diseases caused by arthropod-borne pathogens has been increasing world-wide, facilitated by the expanding range of their vectors, which is in turn aided by a changing climate. Among these, rickettsioses are particularly challenging to control due to difficulties in diagnosis and a lack of vaccines. Rickettsioses occur worldwide and are caused by a diverse array of <italic toggle="yes">Rickettsia</italic> species (Rickettsiales: Rickettsiaceae), with a similarly diverse spectrum of pathogenicity ranging from mild, self-limiting illness to fatal infections [<xref rid="B1-vaccines-13-00109" ref-type="bibr">1</xref>]. Since rickettsiae are primarily transmitted through the bites of ticks, fleas, mites, and lice, the main prevention methods focus on reducing contact with arthropod vectors. The diagnosis of rickettsial diseases is complicated by non-specific symptoms and the reliance on serological methods, which, due to the cross-reactivity of antibodies to multiple <italic toggle="yes">Rickettsia</italic> species, means the causative agent is rarely identified [<xref rid="B2-vaccines-13-00109" ref-type="bibr">2</xref>]. These complications often result in delayed treatment and whilst rickettsioses can be effectively treated with antibiotics, the options are limited to a few antibiotic classes, meaning the development of antibiotic resistance is a future threat to successful treatment, a risk heightened by the current lack of any effective vaccines [<xref rid="B3-vaccines-13-00109" ref-type="bibr">3</xref>]. Despite the severity and potentially high mortality rates of human rickettsioses, there has been little progress towards alleviating these shortcomings due, in part, to the obligate intracellular nature of the causative bacteria, which is further complicated by technically demanding requirements for their safe handling in the laboratory. <italic toggle="yes">Rickettsia rickettsii</italic>, the tick-borne agent of Rocky Mountain spotted fever, and flea-borne <italic toggle="yes">Rickettsia typhi</italic>, as well as louse-borne <italic toggle="yes">Rickettsia prowazekii</italic>, must be handled under BSL3 containment, restricting research with them to appropriately equipped facilities, which are expensive and not readily available. Due to a combination of these factors, progress in rickettsial genetics has been slow and inconsistent [<xref rid="B4-vaccines-13-00109" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00109" ref-type="bibr">5</xref>]. This is a major impediment to the identification of gene function in rickettsial pathogens where more than one third of the genome consists of hypothetical genes. Robust genetic systems for Rickettsiales would facilitate the discovery of unique metabolic pathways that could be targeted for the development of novel therapeutics, and aid in producing effective vaccines [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>].</p><p>Several strategies have been attempted for the development of rickettsial vaccines, including inactivated whole organisms, subunit vaccines, and live attenuated vaccines, although each has its own disadvantages and none have been successfully developed beyond the experimental stage [<xref rid="B7-vaccines-13-00109" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00109" ref-type="bibr">8</xref>]. Additional experimental rickettsial vaccine approaches include recombinant proteins or peptides, DNA or mRNA-based vaccines, antigen-coupled nanoparticles, bacterial or adenovirus vector-based vaccines, and immunization with antigen-presenting cells [<xref rid="B7-vaccines-13-00109" ref-type="bibr">7</xref>]. Live-attenuated vaccines are considered one of the most promising approaches due to their rapid onset of immunity and durable protection. Use of transposon-based systems for the random mutagenesis of rickettsial pathogens can generate libraries of mutants that can form a basis for the selection of attenuated mutants for vaccination studies [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>,<xref rid="B9-vaccines-13-00109" ref-type="bibr">9</xref>]. This methodology has been applied to spotted fever group (SFG) rickettsiae, in particular <italic toggle="yes">Rickettsia parkeri</italic> [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>,<xref rid="B10-vaccines-13-00109" ref-type="bibr">10</xref>], which cause mild disease in humans but induce cross-protective immunity to severe pathogens such as the related agent of Rocky Mountain spotted fever, <italic toggle="yes">R. rickettsii</italic> [<xref rid="B11-vaccines-13-00109" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00109" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00109" ref-type="bibr">13</xref>].</p><p>We showed that <italic toggle="yes">R. parkeri</italic> transposon mutants with an insertion in a phage integrase gene when injected into C3H/HeN mice induced solid protection against challenge with the wild-type strain and, moreover, protected mice against the Mediterranean spotted fever agent, <italic toggle="yes">Rickettsia conorii</italic> [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>]. In addition, we had previously been able to induce the expression of a foreign gene in rickettsiae transformed with shuttle plasmids [<xref rid="B14-vaccines-13-00109" ref-type="bibr">14</xref>]. Based on these successes, we considered that it should be possible to design a genetic tool that would combine the efficiency of the himar1 transposon system with the ability of a recombinase-mediated system for the facile exchange of the transposon with a cassette encoding non-native sequences. To test this idea, we designed a himar1 transposon encoding a fluorescent protein gene and an antibiotic resistance gene to facilitate visualization and selection, flanked by mismatched <italic toggle="yes">loxP</italic> sites to enable subsequent recombinase-mediated cassette exchange (RMCE). In this system, a Cre recombinase catalyzes recombination between specific DNA sequences (<italic toggle="yes">loxP</italic> sites) in a donor plasmid and the intragenically inserted transposon, resulting in the excision and replacement of the transposon sequence with the sequence from the plasmid [<xref rid="B15-vaccines-13-00109" ref-type="bibr">15</xref>]. Mismatched <italic toggle="yes">loxP</italic> sites ensure the desired orientation of the sequence of interest. This approach would allow cassettes encoding desired sequences to be incorporated into the Rickettsiales genome using RMCE. In order to explore the potential of this approach, we designed RMCE cassettes encoding an alternate fluorescent protein gene and selectable marker as well as B-cell epitopes of <italic toggle="yes">Anaplasma phagocytophilum</italic> antigens. These were flanked with the same mismatched <italic toggle="yes">loxP</italic> sequences as the modified himar1 transposon. We reasoned that the marker genes would allow the visualization and enrichment of rickettsiae that had successfully undergone RMCE, and antigenic epitopes from a different Rickettsiales bacterium would allow us to test if these could be correctly expressed, i.e., in such a way that they would be recognized by polyclonal immune sera. By incorporating epitopes of <italic toggle="yes">A. phagocytophilum</italic>, another tick-transmitted member of the Rickettsiales (Family Anaplasmataceae) responsible for human and animal disease worldwide [<xref rid="B16-vaccines-13-00109" ref-type="bibr">16</xref>] and sharing 80&#x02013;86% homology with SFG <italic toggle="yes">Rickettsia</italic> species [<xref rid="B17-vaccines-13-00109" ref-type="bibr">17</xref>], we hoped to provide proof of concept that producing a live-attenuated <italic toggle="yes">Rickettsia</italic> vaccine candidate providing protection from multiple tick-borne diseases is feasible.</p><p>Here, we show that rickettsiae can be manipulated to undergo transposon mutagenesis with subsequent RMCE to replace the transposon with a completely different cassette. An advantage of the RMCE reaction is that the cassette accepts and introduces a much larger payload than the himar1 transposon. Use of this system provides a well-established and relatively efficient way of inserting non-native sequences into the rickettsial genome.</p></sec><sec id="sec2-vaccines-13-00109"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00109"><title>2.1. Bacterial Strains and Cell Types Used</title><p>All experiments were performed using <italic toggle="yes">R. parkeri</italic> Tate&#x02019;s Hell and <italic toggle="yes">A. phagocytophilum</italic> HGE1. <italic toggle="yes">Rickettsia parkeri</italic> were cultured in ISE6 or Vero cells using standard culture conditions [<xref rid="B18-vaccines-13-00109" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00109" ref-type="bibr">19</xref>]. <italic toggle="yes">Anaplasma phagocytophilum</italic> were grown in HL60 cells using established methods [<xref rid="B20-vaccines-13-00109" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot2-vaccines-13-00109"><title>2.2. Production of Rickettsia parkeri Mutant Library and Replacement of Transposon Cassette</title><p>The pLoxHimar plasmid was designed for transposon mutagenesis of rickettsiae, based on our previous successful use of this method in multiple Rickettsiales bacteria [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>,<xref rid="B9-vaccines-13-00109" ref-type="bibr">9</xref>,<xref rid="B21-vaccines-13-00109" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00109" ref-type="bibr">22</xref>]. The well-characterized <italic toggle="yes">Anaplasma marginale tr</italic> promoter [<xref rid="B23-vaccines-13-00109" ref-type="bibr">23</xref>] was used to drive the co-expression of a fluorescent reporter (mCherry) and <italic toggle="yes">aadA</italic> encoding spectinomycin and streptomycin resistance (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>A). Constructs encode both transposase and transposon configured to prevent mobilization of the transposase. The plasmid includes mismatched <italic toggle="yes">loxP-lox5171</italic> and <italic toggle="yes">loxP-lox2272</italic> sites (designated &#x0201c;lox&#x0201d;) flanking the mCherry and <italic toggle="yes">aadA</italic> genes to facilitate excision of the transposon [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>]. An alternative construct with GFPuv and rifampicin resistance (<italic toggle="yes">rif</italic>) genes [<xref rid="B24-vaccines-13-00109" ref-type="bibr">24</xref>] in place of mCherry and <italic toggle="yes">aadA</italic> was also made (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>B) and partial <italic toggle="yes">R. parkeri</italic> libraries were constructed with both of these lox constructs as follows: <italic toggle="yes">R. parkeri</italic> were purified from one 25 cm<sup>2</sup> flask of ISE6 tick cells using mechanical lysis and differential centrifugation [<xref rid="B25-vaccines-13-00109" ref-type="bibr">25</xref>]. They were incubated on ice in 50 &#x000b5;L of 300 mM sucrose for 15 min with 1 &#x000b5;g pLoxHimar plasmid DNA, electroporated at 2 kV, 25 &#x000b5;F and 400 Ohm using a Gene Pulser II (BioRAD, Hercules, CA, USA), and recovered in 100 &#x000b5;L fetal bovine serum (FBS). The bacteria were mixed with ~5 &#x000d7; 10<sup>6</sup> ISE6 tick cells and centrifuged at 5000&#x000d7; <italic toggle="yes">g</italic> for 5 min at room temperature. Centrifuged preparations were left at room temperature for 30 min, and then diluted into 96-well plates pre-seeded with a 50% confluent layer of ISE6 cells at 100 &#x000b5;L/well using L15B300 supplemented with 10% FBS. Antibiotics for selection were added 24 h later in 100 &#x000b5;L of medium to achieve a concentration of 100 &#x000b5;g/mL, and cultures were monitored by fluorescence microscopy to detect marker-expressing rickettsiae. Contents of positive wells were amplified for insertional analysis, as described previously [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>], and storage in liquid nitrogen. &#x0feff;Initially, insertion sites were determined by sequencing rickettsiae from positive wells with primers &#x0201c;Ch Up &#x00026; Out&#x0201d; and &#x0201c;Spec down &#x00026; out&#x0201d; [<xref rid="B26-vaccines-13-00109" ref-type="bibr">26</xref>] for pLoxHimar-transformed <italic toggle="yes">R. parkeri</italic> or &#x0201c;Rif up &#x00026; out&#x0201d; [GACCTTCAAGACCAGATAGTGAC] and &#x0201c;GFPuv down &#x00026; out&#x0201d; [AACGAAAAGCGTGACCAC] for pLoxHimar Rif-GFPuv-transformed <italic toggle="yes">R. parkeri</italic>, which amplify outwards from either end of the transposon into the interrupted gene. For later mutants, insertion sites were determined by whole genome sequencing. Genomic DNA from mutants were pooled in groups of six and whole genome sequencing was performed at the University of Minnesota Genomics Center. Ten Nextera XT DNA libraries were created and then sequenced on a MiSeq 2&#x000d7;250-bp v2 run. Sequencing data were analyzed using MacVector Assembly program. After characterization of desirable mutants, the <italic toggle="yes">GFPuv</italic> and <italic toggle="yes">rif</italic> genes were replaced with a cassette containing <italic toggle="yes">A. phagocytophilum</italic> epitopes, mKate and <italic toggle="yes">aadA</italic>, by RMCE. To do this, <italic toggle="yes">R. parkeri</italic> mutants were electroporated simultaneously with a Cre recombinase-encoding plasmid and pRMCE carrying the poly-epitope sequences, mKate and <italic toggle="yes">aadA</italic>, flanked by the same <italic toggle="yes">lox</italic> sites (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>C&#x02013;E). Loss of <italic toggle="yes">rif</italic> was verified by PCR and exposure of rickettsiae to spectinomycin, alongside wild-type <italic toggle="yes">R. parkeri</italic> as a control. Successful RMCE will result in the replacement of GFPuv with mKate (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>E).</p></sec><sec id="sec2dot3-vaccines-13-00109"><title>2.3. Identification of Attenuated R. parkeri Mutants</title><p>Several <italic toggle="yes">R. parkeri</italic> transposon mutants were assessed for their ability to cause infection in mice. To determine optimal doses for challenge, a range of doses of WT <italic toggle="yes">R. parkeri</italic> from 10<sup>2</sup> to 10<sup>7</sup> were injected intraperitoneally (i.p.) into C3H/HeJ mice (3 age-matched females per group; Jackson Laboratory, Bar Harbor, ME). This mouse strain has been shown to be a good model for SFG rickettsial infections [<xref rid="B27-vaccines-13-00109" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00109" ref-type="bibr">28</xref>] and anaplasmosis [<xref rid="B29-vaccines-13-00109" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00109" ref-type="bibr">30</xref>]. Mice were weighed daily, and percentage body weight loss was calculated. Based on results of dosage testing with WT <italic toggle="yes">R. parkeri</italic>, each purified transposon mutant was inoculated into two mice at a non-lethal dose of 10<sup>3</sup> rickettsiae and weights and tissue loads compared with those of mice inoculated with the same dose of WT <italic toggle="yes">R. parkeri</italic>. Mice were euthanized on days 7 and 14 post infection (p.i.), and samples of organs (heart, liver, lung, spleen) were frozen at &#x02212;20 &#x000b0;C for DNA extraction and qPCR to determine rickettsial loads. DNA was extracted from organs using QIAGEN DNeasy blood and tissue kit (QIAGEN, Hilden, Germany) following manufacturer&#x02019;s instructions. DNA concentration was adjusted so that each well contained an equal amount of DNA, and qPCR was carried out with primers against the citrate synthase (<italic toggle="yes">gltA</italic>) gene [<xref rid="B31-vaccines-13-00109" ref-type="bibr">31</xref>], a single-copy gene in SFG rickettsiae [<xref rid="B32-vaccines-13-00109" ref-type="bibr">32</xref>], using Agilent Brilliant II SYBR Green qPCR master mix (Agilent) on an Mx3000P qPCR System (Stratagene, La Jolla, CA, USA) with cycling conditions as follows: 95 &#x000b0;C 10 min; 40 cycles of 95 &#x000b0;C 30 s, 58 &#x000b0;C 60 s, 72 &#x000b0;C 30 s; and a final dissociation curve of 95 &#x000b0;C 60 s, 58 &#x000b0;C 30 s, 95 &#x000b0;C 30 s. Tissue DNA samples were quantified against a standard curve of 10-fold serially diluted plasmid containing <italic toggle="yes">R. massiliae</italic> citrate synthase. Water was used as a negative control, and all samples were run in triplicate.</p></sec><sec id="sec2dot4-vaccines-13-00109"><title>2.4. Selection of Antigens and Production of Multi-Epitope Arrays</title><p>Epitopes were selected from <italic toggle="yes">A. phagocytophilum</italic> genes encoding known or predicted surface-exposed antigens, including epitopes of the type IV secretory system (T4SS) component VirB9-1 (hereafter virB9), and the surface proteins Asp55 and Asp62 [<xref rid="B33-vaccines-13-00109" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00109" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00109" ref-type="bibr">35</xref>]. VirB9 is conserved among <italic toggle="yes">A. phagocytophilum</italic> strains infecting humans, dogs, and rodents in the US, and differs minimally in strains infecting horses or deer [<xref rid="B36-vaccines-13-00109" ref-type="bibr">36</xref>]. VirB9 is predicted to have a signal peptide and two transmembrane helices; it localizes to the periplasm and surface and is considered a vaccine target [<xref rid="B37-vaccines-13-00109" ref-type="bibr">37</xref>]. Asp55 and Asp62 have multiple transmembrane domains and surface-exposed loops [<xref rid="B35-vaccines-13-00109" ref-type="bibr">35</xref>]. It has been shown that conserved subdominant antigens are suitable vaccine candidates and that components of the T4SS are immunogenic, likely due to their location in the outer membrane [<xref rid="B33-vaccines-13-00109" ref-type="bibr">33</xref>,<xref rid="B37-vaccines-13-00109" ref-type="bibr">37</xref>]. Additionally, the rickettsial YchF gene encoding a ribosome-binding ATPase was included in the first iteration of epitope array designs because of its expected role in enhancing transcription.</p><p>B- and T-cell epitopes from these putative antigens were predicted using Bepipred-2.0 Linear Epitope Prediction [<xref rid="B38-vaccines-13-00109" ref-type="bibr">38</xref>]; Parker Hydrophilicity Prediction [<xref rid="B39-vaccines-13-00109" ref-type="bibr">39</xref>]; Kolaskar and Tongaonkar antigenicity scale [<xref rid="B40-vaccines-13-00109" ref-type="bibr">40</xref>]; Karplus and Schulz flexibility scale [<xref rid="B41-vaccines-13-00109" ref-type="bibr">41</xref>]; Emini surface accessibility scale [<xref rid="B42-vaccines-13-00109" ref-type="bibr">42</xref>]; and Chou and Fasman beta turn prediction [<xref rid="B43-vaccines-13-00109" ref-type="bibr">43</xref>] (<xref rid="vaccines-13-00109-t001" ref-type="table">Table 1</xref>). B-cell epitopes were selected for the following experiments, because antibodies are the most important mediators of immunity during secondary challenge.</p><p>Epitope-coding regions were synthesized as chimeric fusion proteins by GenScript (Piscataway, NJ, USA) with multiple configurations, i.e., with different epitopes included or arranged in a different order, then cloned into plasmid vectors for transformation of <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">R. parkeri</italic>. Epitopes are separated by linkers: S/G P S/G P S/G.</p></sec><sec id="sec2dot5-vaccines-13-00109"><title>2.5. Expression of Epitope Arrays in E. coli</title><p>Epitope arrays were ligated into pET-29a(+) plasmids (Novagen, EMD Millipore, Burlington, MA, USA), then transformed into <italic toggle="yes">E. coli</italic> BL21(DE3) competent cells (New England Biolabs, Ipswich, MA, USA; C2527). Transformed cells were cultured at 37 &#x000b0;C in 2xYT broth and protein expression was induced by addition of 1 mM IPTG for 3 h. Cell pellets were washed in cold PBS then lysed in RIPA buffer (ThermoFisher, Waltham, MA, USA). The lysate was centrifuged, and the supernatant was recovered and boiled for 4 min in 2&#x000d7; Laemmli buffer (BioRAD). Equal amounts of protein (standardized to an equivalent of OD<sub>600</sub> of bacterial cultures) were run on BioRAD Any kD Mini-PROTEAN TGX precast gels at 95 V for 1 h alongside PageRuler pre-stained protein ladder (ThermoFisher) to determine molecular weight. Separated proteins were transferred to a PVDF membrane (EMD Millipore) by wet transfer at 80 V for 1 h. The membrane was blocked for 1 h at RT with PBST + 5% BSA and probed with anti-6HisTag monoclonal antibody conjugated to horseradish peroxidase (ThermoFisher, MA1-21315-HRP) diluted 1:1000 in PBST + 1% BSA for 1 h at RT. Protein detection was carried out with metal-enhanced DAB substrate kit (ThermoFisher, 34065). A second gel was stained with 0.25% Coomassie blue to visualize total protein.</p></sec><sec id="sec2dot6-vaccines-13-00109"><title>2.6. Epitope Antibody Production in Mice</title><p>Protein extracts from transformed <italic toggle="yes">E. coli</italic> were run on 15% wide-well SDS-polyacrylamide gels for 2 h at 70&#x02013;80 V to separate proteins. A strip of 5&#x02013;7 mm corresponding to molecular weight of the epitope of interest was excised from the gel with a scalpel. Protein was purified from gel slices using a modification of a Thermo Scientific protocol [<xref rid="B44-vaccines-13-00109" ref-type="bibr">44</xref>]. Gel slices were placed into a 2 mL tube with 500 &#x000b5;L of elution buffer (50 mM TrisHCl, 150 mM NaCl, 0.1 mM EDTA, pH 7.5). The gel and buffer were then passed 5&#x02013;6 times between two 5 mL syringes to mash the gel. The gel and buffer were incubated overnight at 30 &#x000b0;C shaking at 225 rpm, then centrifuged at 10,000&#x000d7; <italic toggle="yes">g</italic> for 10 min. Supernatant containing eluted protein was pipetted into a new tube. Protein concentration was determined using the BCA protein assay (ThermoFisher).</p><p>Purified epitope peptide was used to immunize mice. Twenty-four C3H/HeJ mice were divided into six treatment groups, each containing four animals: one group for each of the five epitope arrays plus one control group. Injections were prepared using 400 &#x000b5;L TiterMax Gold adjuvant (Sigma Aldrich, Burlington, MA, USA) plus protein in 400 &#x000b5;L elution buffer. Control injections contained adjuvant plus elution buffer only. Emulsions were prepared by adding 200 &#x000b5;L aqueous antigen to 400 &#x000b5;L adjuvant in a 2 mL glass syringe with a 22 G needle and mixing by squeezing in and out of a 1.5 mL tube. When a meringue-like emulsion was formed, the remaining 200 &#x000b5;L antigen was added to the syringe and mixed until completely emulsified. The resulting mixture was divided between four 1 mL syringes to give 4 &#x000d7; 200 &#x000b5;L doses of approximately 50 &#x000b5;g each. Each mouse was injected subcutaneously at four different sites with a 23 G needle. Booster injections of 50 &#x000b5;g, prepared as above, were given four weeks later (day 28 after first immunization). No adverse effects were noted in any mice injected with the recombinant peptide arrays. Two weeks after the booster (day 42), two mice from each group were euthanized with CO<sub>2</sub> and blood was collected by cardiac puncture using a 1 mL syringe with 25 G needle. On day 47 after first immunization, the remaining two mice in each group were challenged with <italic toggle="yes">A. phagocytophilum</italic> (groups 1&#x02013;5; 200 &#x000b5;L <italic toggle="yes">Ap</italic>HGE1-infected HL-60 cells in RPMI 1640 + 10% FBS, taken from a culture of 1.6 &#x000d7; 10<sup>5</sup> cells/mL with 70&#x02013;80% <italic toggle="yes">Ap</italic> infection rate) or <italic toggle="yes">R. parkeri</italic> (group 6; 200 &#x000b5;L cell-free <italic toggle="yes">R. parkeri</italic> in PBS. <italic toggle="yes">Rickettsia parkeri</italic> from purified bacteria preparations were diluted 1:10,000 in PBS, then 20 &#x000b5;L of this were added to 180 &#x000b5;L PBS to make the 200 &#x000b5;L injected). Mice were injected i.p. using a 1 mL syringe fitted with a 25 G needle. Mouse weights were recorded each day following infection. On day 8 post infection, mice were euthanized by CO<sub>2</sub> asphyxiation and their blood, liver, lungs, and spleen were harvested for quantification of bacterial loads by qPCR targeting rickettsial <italic toggle="yes">gltA</italic> (as described above) or <italic toggle="yes">Anaplasma 16S RNA</italic> using PER5/6 primers [<xref rid="B20-vaccines-13-00109" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot7-vaccines-13-00109"><title>2.7. Expression of Epitope Arrays in R. parkeri</title><p>Epitope arrays under control of the <italic toggle="yes">Amtr</italic> promoter were inserted into pRAM18dGSK plasmids [<xref rid="B14-vaccines-13-00109" ref-type="bibr">14</xref>] and transformed into <italic toggle="yes">R. parkeri</italic> Tate&#x02019;s Hell. Transformed bacteria were cultured in ISE6 cells and selected with spectinomycin/streptomycin, as described previously [<xref rid="B19-vaccines-13-00109" ref-type="bibr">19</xref>]. Subsequently, further modifications were made to the array cassette, including replacing the <italic toggle="yes">Amtr</italic> promoter with the <italic toggle="yes">ompA</italic> or <italic toggle="yes">ompB</italic> promoter for improved expression, deletion of YchF sequences, and adding an mKate fluorescent marker for enhanced detection. Various configurations of these improved arrays were inserted into pRAM18dGSK plasmids for transformation of <italic toggle="yes">R. parkeri.</italic> The transformed bacteria were cultured in ISE6 and Vero cells and selected with spectinomycin/streptomycin at 50 &#x003bc;g/mL. Successful transformation and expression of epitope arrays were then assessed using fluorescent microscopy, PCR, RT-PCR, and Western blotting as described below.</p><p>Low subpassage <italic toggle="yes">R. parkeri</italic> G8::lox mutant (with a loxHimar insertion in the RPATATE_1142 gene encoding an N-acetylmuramoyl-L-alanine amidase family protein) transformed with pRAM18dGSK plasmids containing various epitope combinations fused to an mKate fluorescent protein, and <italic toggle="yes">R. parkeri</italic> G8::lox mutants with the epitope-mKate cassette swapped into the himar insertion site via RMCE were grown in ISE6 cells. Successful transformations were confirmed by antibiotic selection, fluorescent microscopy, PCR, RT-PCR, and Western blotting.</p><p>Genomic DNA was made from all <italic toggle="yes">R. parkeri</italic> transformants with the PureGene Core Kit A (QIAGEN) as per the manufacturer&#x02019;s protocol for gram negative bacteria. <italic toggle="yes">Rickettsia parkeri</italic> transformed with pRAM18dSGK[epitopes] were tested for the presence of the epitope cassette with primers M13F/MCS193R (<xref rid="app1-vaccines-13-00109" ref-type="app">Table S1</xref>) and GoTaq DNA Polymerase (Promega) in standard PCR reactions with the following cycling parameters: 1 cycle at 95 &#x000b0;C for 2 min; 40 cycles at 95 &#x000b0;C for 30 s, 50 &#x000b0;C for 30 s, 1 min at 72 &#x000b0;C; and a final 7 min period at 72 &#x000b0;C.</p><p>The <italic toggle="yes">R. parkeri</italic> G8::lox mutant that had undergone RMCE with the Cre plasmid (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>D) and pRMCE constructs containing various epitopes fused to mKate and the Spectinomycin resistance gene flanked by the inverted lox repeat sites (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>C) were tested for purity with the primer sets RPATATE_1142 F2/ ID2, RPATATE_1142 F2/ rif Up &#x00026; Out, and RPATATE_1142 F2/ mKATE Up &#x00026; Out2 using Q5High Fidelity DNA Polymerase (New England Biolabs) as per the manufacturer&#x02019;s protocol with the following cycling parameters: 1 cycle 98 &#x000b0;C for 30 s, 40 cycles of 98 &#x000b0;C for 10 s, X &#x000b0;C for 30 s, and 72 &#x000b0;C for 30 s, with a final extension step of 2 min at 72 &#x000b0;C, where X is 66 &#x000b0;C, 65 &#x000b0;C, or 67 &#x000b0;C for each primer set, respectively.</p><p><italic toggle="yes">R. parkeri</italic> transformed with pRAM18dSGK[epitopes] were extracted from host cells as described above and put into RNAProtect (QIAGEN) as per manufacturer&#x02019;s protocol, except pellets were recovered from RNAProtect at 5000&#x000d7; <italic toggle="yes">g</italic> for 15 min to ensure collection of rickettsiae. Recovered pellets were resuspended in 1 mL TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) and vortexed, and RNA was prepared using the Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA) as per manufacturer&#x02019;s protocol. RNA was treated with gDNA Eraser (TaKaRa, San Jose, CA, USA) to remove genomic DNA, and 100 ng of resulting RNA was added to qRT-PCR Brilliant II SYBR 1-step Master Mix reactions (Agilent, Santa Clara, CA, USA) following the manufacturer&#x02019;s protocol. Samples were run in an Mx3005 qPCR cycler (Stratagene) with 240 nM of each primer, with or without RT, with cycling parameters as follows: 1 cycle at 50 &#x000b0;C for 30 min, 1 cycle at 95 &#x000b0;C for 10 min, 40 cycles of 95 &#x000b0;C for 30 s, 52 &#x000b0;C for 1 min and 72 &#x000b0;C for 45 s, and a dissociation curve cycle of 95 &#x000b0;C for 1 min, 52 &#x000b0;C for 30 s, and 95 &#x000b0;C for 30 s to confirm product specificity. If larger products were predicted, RNA samples were run with the Access RT-PCR kit (Promega, Madison, WI, USA) as per manufacturer&#x02019;s protocol. Products were run on 1.5% agarose gels to visualize results. Primers targeted epitope sequences, and GFPuv (present on pRAM18dSGK) primers were used for quality control.</p><p>Protein from <italic toggle="yes">R. parkeri</italic> cultures was extracted using CelLytic B Cell Lysis Reagent (Sigma-Aldrich), then boiled for 4 min in 4&#x000d7; Laemmli buffer (BioRAD) before separation by SDS-PAGE on Any kD Mini PROTEAN precast gels (BioRAD). Proteins were transferred to a PVDF membrane and probed with antibodies against mKate (1:500; ThermoFisher monoclonal antibody TA180091) or GFPuv (1:1000; Novus Biologicals monoclonal antibody MAB4240; Centennial, CO, USA), then secondary antibodies (goat anti-mouse IgG HRP conjugate (ThermoFisher G-21040), 1:10,000). Protein detection was performed using a Pierce ECL kit (ThermoFisher).</p></sec><sec id="sec2dot8-vaccines-13-00109"><title>2.8. Preparation of Rickettsiae for Inoculation of Mice</title><p>Wild-type and transformed mutant <italic toggle="yes">R. parkeri</italic> were grown in Vero cells at 34 &#x000b0;C and 4% CO<sub>2</sub> in RPMI1640 (Gibco, ThermoFisher) supplemented with 10% FBS. Host cell-free rickettsiae were isolated from heavily infected Vero cells by vortexing with 60/90 rock tumbler grit (Lortone, Mukilteo, WA, USA), followed by passage through a 2 &#x000b5;m pore size filter to remove host cell debris, and centrifugation at 13,200&#x000d7; <italic toggle="yes">g</italic> for 5 min at 4 &#x000b0;C to pellet bacteria, as described previously [<xref rid="B19-vaccines-13-00109" ref-type="bibr">19</xref>]. Rickettsiae were then resuspended in RPMI1640 with 20% FBS and 10% DMSO, aliquoted into cryovials and stored in liquid nitrogen. To quantify the number of infectious bacteria per aliquot, cryovials were thawed in a 37 &#x000b0;C water bath, spun down, and the cell pellet resuspended in 0.6 mL fresh medium. A volume of 100 &#x000b5;L of rickettsiae were then added to replicate wells of a 24-well plate containing confluent Vero cells, centrifuged at 1500&#x000d7; <italic toggle="yes">g</italic> for 5 min and then incubated at 37 &#x000b0;C for 2 h. Wells were then washed twice with PBS to remove external rickettsiae, trypsin-treated to detach cells, and resuspended in 0.5 mL growth medium. Cells were spun down, and DNA was extracted using a Puregene kit (QIAGEN) following the manufacturer&#x02019;s Gram-negative bacteria protocol. Quantification of <italic toggle="yes">R. parkeri</italic> in each sample was performed with qPCR targeting the <italic toggle="yes">gltA</italic> gene, as described above.</p></sec><sec id="sec2dot9-vaccines-13-00109"><title>2.9. Mouse Challenge Experiments to Test Efficacy of Attenuated R. parkeri Mutant Expressing A. phagocytophilum Epitope Arrays</title><p>On day 0, twenty-one four-week-old female C3H/HeJ mice (Jackson Laboratory) were injected i.p. with 1 &#x000d7; 10<sup>5</sup>&#x000a0;<italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] in 200 &#x003bc;L PBS, and nine were inoculated with 200 &#x003bc;L PBS as controls. Mice were sorted into groups of three, and each group was weighed together daily throughout the experiment and monitored for signs of illness. Three days later, one group of vaccinated mice were euthanized and organs (heart, liver, lungs, spleen) were collected for determination of infection with the vaccine strain. On day 28, nine immunized mice were given a booster dose containing 1 &#x000d7; 10<sup>5</sup>&#x000a0;<italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] in 200 &#x003bc;L PBS. The other nine immunized mice and nine control mice were injected with 200 &#x003bc;L PBS. Seven days later (day 35), three mice from each group were sacrificed for collection of serum and organs for assessment of immune response to <italic toggle="yes">R. parkeri</italic> and <italic toggle="yes">A. phagocytophilum,</italic> and infection with the vaccine strain. Organs were stored at &#x02212;20 &#x000b0;C for DNA extraction. On day 42, the remaining vaccinated and control mice were inoculated i.p. with either 1 &#x000d7; 10<sup>6</sup>&#x000a0;<italic toggle="yes">R. parkeri</italic> WT in 200 &#x003bc;L PBS (three mice/group) or 200 &#x003bc;L HL-60 culture infected (&#x0003e;50%) with <italic toggle="yes">A. phagocytophilum</italic> HGE1, containing approximately 1 &#x000d7; 10<sup>5</sup> infected cells (three mice/group). Mice challenged with <italic toggle="yes">R. parkeri</italic> were euthanized three days post challenge (day 45), and serum and organs collected as above. Those challenged with <italic toggle="yes">A. phagocytophilum</italic> were euthanized seven days post challenge [<xref rid="B30-vaccines-13-00109" ref-type="bibr">30</xref>,<xref rid="B45-vaccines-13-00109" ref-type="bibr">45</xref>], for collection of serum and organs. About 35 &#x000b5;L of blood taken from these mice was transferred to flasks of approximately 1 &#x000d7; 10<sup>6</sup> HL-60 to assess <italic toggle="yes">A. phagocytophilum</italic> infection by examination of Giemsa-stained cells and PCR using PER1/2 primers against the 16S RNA gene [<xref rid="B20-vaccines-13-00109" ref-type="bibr">20</xref>]. Spleen weights were measured from mice euthanized on days 35, 45, and 49.</p></sec><sec id="sec2dot10-vaccines-13-00109"><title>2.10. Quantification of Bacterial Load in Mouse Tissues</title><p><italic toggle="yes">Rickettsia parkeri</italic> were quantified using qPCR against the single copy <italic toggle="yes">gltA</italic> gene, as described above. <italic toggle="yes">Anaplasma phagocytophilum</italic> load was measured with a qPCR assay targeting the <italic toggle="yes">msp5</italic> gene [<xref rid="B46-vaccines-13-00109" ref-type="bibr">46</xref>] using 10-fold serial dilutions of an <italic toggle="yes">msp5</italic>-containing plasmid as a standard curve.</p></sec><sec id="sec2dot11-vaccines-13-00109"><title>2.11. Immunofluorescence Assays</title><p>HL-60 cells infected with <italic toggle="yes">A. phagocytophilum</italic>, at a level of 80&#x02013;90%, were resuspended in PBS and added to 18-well slides with approximately 2 &#x000d7; 10<sup>3</sup> cells per well. Slides were air-dried, then fixed in acetone for 8 min [<xref rid="B47-vaccines-13-00109" ref-type="bibr">47</xref>]. Slides were blocked with FBS overnight at 4 &#x000b0;C in a humid chamber. Blocking agent was removed and pooled sera from mice, diluted at 1:50, 1:100, 1:200, 1:400, 1:800, and 1:1600 in PBST + 1% BSA, were added to slides in triplicate and incubated at RT for 1 h in a humid chamber. Slides were washed 3&#x000d7; in PBST, then secondary antibody (AlexaFluor488-conjugated goat anti-mouse, 1:1500 in PBST + 1% BSA) was added and incubated at RT for 1 h in a humid chamber. Slides were washed 3&#x000d7; in PBST, allowed to dry, and viewed by fluorescence microscopy on an Olympus BX61 confocal microscope at 40&#x000d7; magnification. IFAs against <italic toggle="yes">R. parkeri</italic> were performed with <italic toggle="yes">R. parkeri-</italic>infected ISE6 cells using a similar protocol.</p></sec><sec id="sec2dot12-vaccines-13-00109"><title>2.12. Enzyme-Linked Immunosorbent Assays</title><p>Each recombinant epitope peptide array was diluted in freshly prepared 50 mM carbonate&#x02013;bicarbonate buffer and used to coat a 96-well Nunc Immuno polysorb ELISA plate with 500 ng per well. Plates were blocked for 3 h with PBST + 5% BSA, then incubated 2 h with sera from recombinant protein-immunized mice at 1:100 dilution. Secondary antibody (goat anti-mouse IgG, AlexFluor488) was added at 1:2000 for 1 h. Fluorescence was measured at 485/528 on a BioTek Synergy H1 microplate reader, and readings were adjusted to the negative control (secondary antibody only). Wells were washed 3&#x000d7; with PBST between each step and all incubations were performed at RT. Each treatment was tested in triplicate wells.</p><p>To test reactivity of sera from mice vaccinated with the transformed <italic toggle="yes">R. parkeri</italic> G8::lox mutant, bacteria (<italic toggle="yes">R. parkeri</italic> WT, <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate], and <italic toggle="yes">A. phagocytophilum</italic>) were isolated from cell culture as described above, resuspended in 50 mM carbonate&#x02013;bicarbonate buffer, and approximately 1 &#x000d7; 10<sup>8</sup> bacteria in 100 &#x000b5;L were pipetted into wells of a 96-well Nunc Maxisorp Immuno ELISA plate (Thermo Scientific). The plate was incubated overnight at 4 &#x000b0;C, washed 3&#x000d7; with PBST, then blocked with PBST + 5% nonfat dry milk for 2 h at RT. After washing 3&#x000d7; in PBST, pooled mouse sera (1:100 in PBST + 1% milk) were added to each well for 1 h, followed by another wash 3&#x000d7; in PBST, and 1 h incubation with secondary antibody (HRP-conjugated goat anti-mouse, 1:10,000 in PBST + 1% milk). Wells were then washed 3&#x000d7; in PBST, and TMB substrate (Thermo Scientific 1-Step Ultra TMB-ELISA) was added to each well for 20 min, followed by addition of 2M hydrochloric acid to stop the reaction. Absorbance was read at 450 nm on a BioTek Synergy H1 microplate reader and readings were adjusted to a blank control containing no bacteria to which no sera were added. Each treatment was tested in triplicate wells, with uncoated wells and wells without serum added, acting as further negative controls.</p></sec><sec id="sec2dot13-vaccines-13-00109"><title>2.13. Statistics</title><p>Statistical analyses were conducted in GraphPad Prism version 10. One-way ANOVA was used to compare pathogen loads or spleen weights between different mouse groups, whereas a two-way ANOVA was used to analyze <italic toggle="yes">A. phagocytophilum</italic> infection of cell cultures over time and by vaccination status. A <italic toggle="yes">p</italic>-value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00109"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00109"><title>3.1. Production of R. parkeri Transposon Mutants</title><p>A library of 80 <italic toggle="yes">R. parkeri</italic> mutants was generated using himar1 transposon mutagenesis for the random insertion of a himar1 transposon into TA dinucleotides in the <italic toggle="yes">R. parkeri</italic> genome (<xref rid="app1-vaccines-13-00109" ref-type="app">Table S2</xref>). The transposon was designed to be flanked with mismatched lox sequences for subsequent replacement using RMCE catalyzed by the Cre recombinase enzyme (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>E), described in detail in the Methods Section. The library included 54 mutants with the transposon inserted intragenically and 26 with intergenic insertions. Twelve mutants were generated with the GFPuv/rif transposon, and the remaining sixty-eight mutants contained the mCherry/aadA transposon. Details of all generated transposon mutants are provided in <xref rid="app1-vaccines-13-00109" ref-type="app">Table S2</xref>.</p></sec><sec id="sec3dot2-vaccines-13-00109"><title>3.2. Mouse Infectivity of Transposon Mutants</title><p>The results of WT <italic toggle="yes">R. parkeri</italic> dosage testing in mice indicated that the injection of 10<sup>7</sup> or 10<sup>6</sup> bacteria resulted in severe illness by day 3&#x02013;4, requiring euthanasia. Mice in the other dosage groups initially gained weight but started to lose weight from days 3&#x02013;4, indicating that infection had occurred and rickettsiae were replicating. Therefore, in initial experiments to test the infectivity of transposon mutants, a non-lethal dose of 10<sup>3</sup>&#x000a0;<italic toggle="yes">R. parkeri</italic> per mouse was used. Several mutants were found to be attenuated in infection when compared with WT <italic toggle="yes">R. parkeri</italic> in these preliminary in vivo experiments. The mutational analysis of gene function in rickettsiae is limited and has not always yielded the anticipated results [<xref rid="B5-vaccines-13-00109" ref-type="bibr">5</xref>,<xref rid="B48-vaccines-13-00109" ref-type="bibr">48</xref>]. Therefore, seven mutants were selected based on a range of expected phenotypes from insertions in genes predicted to be important for infection (such as <italic toggle="yes">ompB</italic>)<italic toggle="yes">,</italic> insertions in genes of unknown function, and intergenic insertions expected to have no effect. Infection with these seven <italic toggle="yes">R. parkeri</italic> mutants was assessed in C3H/HeJ mice at 7- and 14-days post infection in comparison with WT <italic toggle="yes">R. parkeri</italic>. None of the mutants induced weight loss in the infected mice, whereas mice infected with WT lost on average 2.8 g by day 7, equating to approximately 10% weight loss (<xref rid="vaccines-13-00109-f002" ref-type="fig">Figure 2</xref>A). Of seven mutants tested, mutant 2 showed a similar rickettsial load in mouse tissues to those infected with WT <italic toggle="yes">R. parkeri</italic>, whilst mutants 4, 5, and 7 showed greatly reduced tissue loads, and <italic toggle="yes">R. parkeri</italic> were not detected in tissues for mutants 1, 3, and 6 (<xref rid="vaccines-13-00109-f002" ref-type="fig">Figure 2</xref>B). By day 14, neither WT nor mutant <italic toggle="yes">R. parkeri</italic> were detected in mouse tissues.</p></sec><sec id="sec3dot3-vaccines-13-00109"><title>3.3. Development of Anaplasma Epitope Arrays for Expression in R. parkeri</title><p>We aimed to employ the RMCE system to insert a cassette containing sequences of predicted <italic toggle="yes">A. phagocytophilum</italic> epitopes into an attenuated <italic toggle="yes">R. parkeri</italic> transposon mutant as a potential method for producing an attenuated vaccine strain protective against both rickettsiosis and anaplasmosis. Epitopes were selected bioinformatically from surface-exposed antigens of <italic toggle="yes">A. phagocytophilum</italic> that appear to be involved in host cell invasion [<xref rid="B35-vaccines-13-00109" ref-type="bibr">35</xref>], based on predicted linear B-cell epitopes and antigenicity (see Methods <xref rid="sec2dot4-vaccines-13-00109" ref-type="sec">Section 2.4</xref>). Various configurations of the epitope array cassette were designed and first tested in <italic toggle="yes">E. coli</italic> and WT <italic toggle="yes">R. parkeri</italic> to confirm that they could be correctly expressed. Different configurations of the initial design of the epitope arrays were expressed in <italic toggle="yes">E. coli</italic> (<xref rid="vaccines-13-00109-f003" ref-type="fig">Figure 3</xref>) and purified for the production of antibodies in mice. IFA showed that the serum of mice injected with all epitope arrays was reactive with <italic toggle="yes">A. phagocytophilum</italic> in HL-60 cells (<xref rid="app1-vaccines-13-00109" ref-type="app">Figure S1A</xref>). Mouse sera also recognized the epitope protein to which they had been immunized in a peptide ELISA, although due to the presence of YchF in all arrays, there was cross-reactivity of mouse sera to all epitope configuration peptides (<xref rid="app1-vaccines-13-00109" ref-type="app">Figure S1B</xref>).</p><p>Mice immunized with purified epitope protein showed similar weight gain compared with the negative control mice but exhibited reduced loads of <italic toggle="yes">A. phagocytophilum</italic> in tissues 8 dpi (<xref rid="vaccines-13-00109-f004" ref-type="fig">Figure 4</xref>A,B), suggesting a protective effect of the epitope immunization, although due to the small number of animals used, this was only significant for <italic toggle="yes">Anaplasma</italic> loads in liver for two of the epitope combinations. In contrast, mice immunized with the YchF epitope alone showed no protection from <italic toggle="yes">R. parkeri</italic> challenge, with mice becoming severely ill (requiring euthanasia) within a week of infection (<xref rid="vaccines-13-00109-f004" ref-type="fig">Figure 4</xref>A,C). This result may be explained by the fact that YchF plays a role in bacterial stress response pathways [<xref rid="B49-vaccines-13-00109" ref-type="bibr">49</xref>]; however, because a detailed investigation of this phenomenon was outside the scope of this project, we decided to delete YchF epitopes from future iterations of the arrays.</p><p>Following successful expression in <italic toggle="yes">E. coli</italic>, epitope arrays were ligated into the pRAM18dSGK rickettsial shuttle vector [<xref rid="B14-vaccines-13-00109" ref-type="bibr">14</xref>] for expression in WT <italic toggle="yes">R. parkeri.</italic> Probing Western blots of protein extracts from transformed rickettsiae with anti-His-tag antibodies failed to detect the expression of epitope proteins at the expected sizes. Therefore, attempts were made to improve the chances of successful peptide array expression and translation by replacing the <italic toggle="yes">Amtr</italic> promoter with the native rickettsial <italic toggle="yes">ompA</italic> or <italic toggle="yes">ompB</italic> promoters. However, the expression of the epitope arrays was not detected by anti-His antibodies using either <italic toggle="yes">omp</italic> promoter, irrespective of growing rickettsiae in ISE6 or Vero cells. As a control, Western blot with anti-GFPuv antibodies confirmed the presence of GFPuv protein resulting from successful expression from the shuttle plasmid. Finally, epitope constructs were created that included an mKate fusion adjacent to the His-tag, allowing direct detection of expression of the epitope cassette in successfully transformed <italic toggle="yes">R. parkeri.</italic> In total, 32 variations of the cassette were constructed and inserted into the pRAM18dSGK shuttle plasmid; a complete list of all configurations is included in <xref rid="vaccines-13-00109-t002" ref-type="table">Table 2</xref>. Twenty-three of these were successfully transformed into <italic toggle="yes">R. parkeri</italic> and the presence of the correct size transcripts was observed for most constructs by RT-PCR, indicating successful expression in transformed rickettsiae (<xref rid="vaccines-13-00109-t002" ref-type="table">Table 2</xref>; <xref rid="app1-vaccines-13-00109" ref-type="app">Figure S2</xref>). The translation of mKate-epitope fusion protein and GFPuv was examined by Western blotting and fluorescent microscopy in a subset of these transformants (<xref rid="vaccines-13-00109-f005" ref-type="fig">Figure 5</xref>). Whilst GFPuv was detected in all plasmid-transformed samples (<xref rid="vaccines-13-00109-f005" ref-type="fig">Figure 5</xref>A), confirming the acquisition of the shuttle vector, mKate expression was only detected in <italic toggle="yes">R. parkeri</italic> transformed with shuttle vectors containing the virB9-mKate and Asp62-mKate sequences but not the Asp55-Asp62-virB9-mKate or Asp62-virB9-mKate sequences (<xref rid="vaccines-13-00109-f005" ref-type="fig">Figure 5</xref>B,C). The presence/absence of red-fluorescent rickettsiae during the visualization of transformed <italic toggle="yes">R. parkeri</italic> by fluorescent microscopy confirmed these results (<xref rid="vaccines-13-00109-f005" ref-type="fig">Figure 5</xref>D,E). Plasmid expression of the virB9 epitope appeared to be higher than that of the Asp62 epitope (<xref rid="vaccines-13-00109-f005" ref-type="fig">Figure 5</xref>C).</p><p>Due to the addition of the mKate reporter to the epitope arrays, we were constrained to using transposon mutants with a GFPuv/rif transposon insertion for subsequent RMCE introducing epitope arrays. A transposon mutant (designated <italic toggle="yes">R. parkeri</italic> G8::lox) with an insertion into the RPATATE_1142 gene encoding an N-acetylmuramoyl-L-alanine amidase family protein was selected for further genetic modification using RMCE to incorporate epitope arrays (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>A). Based on the successful expression of virB9-mKate and Asp62-mKate from shuttle vectors in WT <italic toggle="yes">R. parkeri</italic>, the <italic toggle="yes">R. parkeri</italic> G8::lox transposon mutant was transformed with pRAM18dSGK shuttle vectors containing different configurations of epitopes fused to mKate. Similar to in WT, the expression of epitope-mKate fusion protein was detected only in the <italic toggle="yes">R. parkeri</italic> G8::lox transformants expressing virB9-mKate and Asp62-mKate from the plasmid by both Western blotting and fluorescent microscopy (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>).</p><p>The G8::lox transposon mutant was separately transformed with RMCE plasmids (<xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>) to replace the mutant&#x02019;s intragenic GFPuv/rif sequence resulting from genome insertion mutagenesis with either the virB9-mKate or the Asp62-mKate cassette (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>A). Western blot analysis detected mKate expression in <italic toggle="yes">R. parkeri</italic> G8::lox with the virB9-mKate insertion but not with the Asp62-mKate insertion (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>B). GFPuv was detected in all transformants expressing the pRAM18dGSK plasmid but not in the two RMCE mutants, indicating a successful replacement of the loxHimar insertion containing GFPuv with the epitope-mKate-containing cassette (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>B). The expression of virB9-mKate following RMCE in <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] was also confirmed by RT-PCR (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>C). The Western blot results were consistent with fluorescence microscopy findings for each transformant (<xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>D&#x02013;G).</p></sec><sec id="sec3dot4-vaccines-13-00109"><title>3.4. Testing Immunogenicity of Epitope Arrays In Vivo</title><p>We reasoned that an attenuated <italic toggle="yes">R. parkeri</italic> transposon mutant expressing <italic toggle="yes">A. phagocytophilum</italic> epitopes could be used as a live-attenuated vaccine to induce broad protective immunity against SFG rickettsiae and <italic toggle="yes">A. phagocytophilum</italic> in mice. Thus, we immunized mice with <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] and challenged animals with either WT <italic toggle="yes">R. parkeri</italic> or <italic toggle="yes">A. phagocytophilum</italic>. Different groups of mice received either a single inoculation of 1 &#x000d7; 10<sup>5</sup>
<italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] at day 0 (&#x0201c;vaccinated&#x0201d; group), or the same treatment at day 0 followed by a booster dose containing the same number of <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] at day 28 (&#x0201c;boosted&#x0201d; group; <xref rid="vaccines-13-00109-f007" ref-type="fig">Figure 7</xref>). A control group received PBS injections at days 0 and 28. On day 35, three mice from each group were euthanized to obtain serum for antibody investigation and tissue samples to determine the persistence of <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate]. On day 42, all mice were challenged with either 1 &#x000d7; 10<sup>6</sup> WT <italic toggle="yes">R. parkeri</italic> or 1 &#x000d7; 10<sup>5</sup> HL60 cells infected with <italic toggle="yes">A. phagocytophilum</italic>. The <italic toggle="yes">R. parkeri</italic>-challenged mice were euthanized three days later whilst <italic toggle="yes">A. phagocytophilum</italic>-challenged mice were euthanized seven days later, to take into account the different courses of infection of each pathogen (<xref rid="vaccines-13-00109-f007" ref-type="fig">Figure 7</xref>).</p><p>All mouse groups gradually gained weight after initial vaccination (<xref rid="vaccines-13-00109-f008" ref-type="fig">Figure 8</xref>A,B). Following the day 28 booster dose or PBS injection, there was a slight drop or levelling off of weight gain in multiple groups, although mice appeared to recover. Following challenge with WT <italic toggle="yes">R. parkeri</italic>, the unvaccinated control group appeared visibly ill, exhibiting ruffled fur and hunched postures, and showed a dramatic weight loss of approximately 10%, whereas the vaccinated and boosted groups displayed no weight loss or other conditions indicative of disease (<xref rid="vaccines-13-00109-f008" ref-type="fig">Figure 8</xref>A). As expected, no signs of illness were observed in mice challenged with <italic toggle="yes">A. phagocytophilum</italic>, although the boosted group showed a slight loss of weight (<xref rid="vaccines-13-00109-f008" ref-type="fig">Figure 8</xref>B). There were no differences in spleen weight between control, vaccinated, and boosted groups of mice at days 35, 45, or 49 (<xref rid="vaccines-13-00109-f008" ref-type="fig">Figure 8</xref>C); the only significant differences observed in spleen weight corresponded to time, i.e., before and after challenge (day 35 vs. day 45 or 49).</p><p>Rickettsiae were not detected in tissues of mice that had been vaccinated or boosted (<xref rid="vaccines-13-00109-f009" ref-type="fig">Figure 9</xref>A), which was significantly different from control mice for liver (<italic toggle="yes">p</italic> = 0.0079), lung (<italic toggle="yes">p</italic> &#x0003c; 0.0001), and spleen (<italic toggle="yes">p</italic> = 0.0407) but not for heart (<italic toggle="yes">p</italic> = 0.0803). In contrast, vaccinated and boosted mice appeared to have little immunological protection from challenge with <italic toggle="yes">A. phagocytophilum</italic> (<xref rid="vaccines-13-00109-f009" ref-type="fig">Figure 9</xref>B); <italic toggle="yes">Anaplasma</italic> loads were similar across groups in liver (<italic toggle="yes">p</italic> = 0.1606) and spleen (<italic toggle="yes">p</italic> = 0.5674), and although they were higher in heart tissues of control mice, this was not significant (<italic toggle="yes">p</italic> = 0.0849). However, <italic toggle="yes">Anaplasma</italic> loads in the lung was slightly higher in the control mice (<italic toggle="yes">p</italic> = 0.0487) than in the vaccinated or boosted groups (<xref rid="vaccines-13-00109-f009" ref-type="fig">Figure 9</xref>B). Furthermore, blood cultures prepared from <italic toggle="yes">A. phagocytophilum</italic>-challenged mice showed no significant differences based on vaccination status, with infection progressing similarly in cultures prepared from control, vaccinated, and boosted mice (<xref rid="vaccines-13-00109-f010" ref-type="fig">Figure 10</xref>A). The presence of <italic toggle="yes">A. phagocytophilum</italic> DNA was confirmed in all blood cultures by PCR (<xref rid="vaccines-13-00109-f010" ref-type="fig">Figure 10</xref>B).</p><p>The analysis of mouse tissues for the persistence of <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] at day 3 after initial vaccination showed that numbers of rickettsiae were very low, indicative of an attenuated infection phenotype, whilst at day 35 (7 days after booster) and day 49, rickettsiae were undetectable or extremely low (<xref rid="app1-vaccines-13-00109" ref-type="app">Figure S3</xref>).</p><p>IFA using serum from vaccinated and boosted mice taken at day 35 showed a strong labeling of WT <italic toggle="yes">R. parkeri</italic> in ISE6 cells at all dilutions tested (<xref rid="vaccines-13-00109-f010" ref-type="fig">Figure 10</xref>C), indicating a significant antibody response, and was stronger than that of serum from control mice taken at day 45 (3 dpi after infection with WT <italic toggle="yes">R. parkeri</italic> (<xref rid="vaccines-13-00109-f007" ref-type="fig">Figure 7</xref>)). This difference may be due to the insufficient time for the control mice to develop a strong antibody response. Sera from vaccinated and boosted mice also labelled <italic toggle="yes">A. phagocytophilum</italic> morulae within infected HL-60 cells at dilutions of up to 1:200 (<xref rid="vaccines-13-00109-f010" ref-type="fig">Figure 10</xref>D). ELISA comparing sera from vaccinated and boosted mice tested in wells containing either <italic toggle="yes">A. phagocytophilum</italic>, WT <italic toggle="yes">R. parkeri</italic>, or <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] showed binding to <italic toggle="yes">R. parkeri</italic>-coated wells but not to <italic toggle="yes">A. phagocytophilum</italic>-coated wells (<xref rid="vaccines-13-00109-f010" ref-type="fig">Figure 10</xref>E). Interestingly, sera from <italic toggle="yes">A. phagocytophilum</italic>-infected mice showed reactivity to <italic toggle="yes">R. parkeri</italic>-coated wells, as well as to <italic toggle="yes">A. phagocytophilum</italic>-containing wells. Sera from vaccinated and boosted mice bound more strongly to wells coated with <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] than to those coated with WT <italic toggle="yes">R. parkeri</italic>.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00109"><title>4. Discussion</title><p>The obligate intracellular nature of the Rickettsiales has made the genetic manipulation of these bacteria extremely difficult until relatively recently [<xref rid="B50-vaccines-13-00109" ref-type="bibr">50</xref>], which has been a major obstacle to investigating gene function. The application of transposon mutagenesis to <italic toggle="yes">A. phagocytophilum</italic> [<xref rid="B21-vaccines-13-00109" ref-type="bibr">21</xref>] and <italic toggle="yes">R. prowazekii</italic> [<xref rid="B4-vaccines-13-00109" ref-type="bibr">4</xref>,<xref rid="B24-vaccines-13-00109" ref-type="bibr">24</xref>] paved the way for the development of this tool for use in other pathogenic Rickettsiales including <italic toggle="yes">A. marginale</italic> [<xref rid="B51-vaccines-13-00109" ref-type="bibr">51</xref>], <italic toggle="yes">Ehrlichia chaffeensis</italic> [<xref rid="B22-vaccines-13-00109" ref-type="bibr">22</xref>], and <italic toggle="yes">R. parkeri</italic> [<xref rid="B10-vaccines-13-00109" ref-type="bibr">10</xref>,<xref rid="B52-vaccines-13-00109" ref-type="bibr">52</xref>]<italic toggle="yes">,</italic> although it remains a challenging approach. The development of shuttle vectors allowing the stable transformation of genes of interest into diverse <italic toggle="yes">Rickettsia</italic> species [<xref rid="B14-vaccines-13-00109" ref-type="bibr">14</xref>] enabled the complementation of genes knocked out by transposon mutagenesis in <italic toggle="yes">R. parkeri</italic> [<xref rid="B10-vaccines-13-00109" ref-type="bibr">10</xref>]. Using these genetic tools, rickettsiologists have begun to uncover the function of genes required for pathogenesis, and the recent implementation of conditional gene expression and CRISPR interference-mediated knockdown in <italic toggle="yes">R. parkeri</italic> [<xref rid="B53-vaccines-13-00109" ref-type="bibr">53</xref>] and <italic toggle="yes">R. rickettsii</italic> [<xref rid="B54-vaccines-13-00109" ref-type="bibr">54</xref>] will further accelerate discovery. Here, we have further modified the transposon mutagenesis approach to allow the exchange of sequences carried within the transposon with sequences of interest, which may be used for the complementation of the mutagenized gene, the expression of non-native sequences, or the analysis of non-coding RNAs and regulatory elements. Advantages of this system include the ability to introduce larger sequences than can be inserted by transposon mutagenesis and the stable intragenic expression of the inserted gene of interest.</p><p>Transposon mutagenesis of certain <italic toggle="yes">R. parkeri</italic> genes results in an attenuated infection phenotype [<xref rid="B6-vaccines-13-00109" ref-type="bibr">6</xref>,<xref rid="B10-vaccines-13-00109" ref-type="bibr">10</xref>,<xref rid="B55-vaccines-13-00109" ref-type="bibr">55</xref>]; this has been attributed to the roles of specific gene products in cell&#x02013;cell spread [<xref rid="B10-vaccines-13-00109" ref-type="bibr">10</xref>] or the evasion of host immune responses [<xref rid="B55-vaccines-13-00109" ref-type="bibr">55</xref>]. We identified a range of additional <italic toggle="yes">R. parkeri</italic> genes whose mutation resulted in reduced in vivo infectivity and should be investigated further to provide insights into the roles that these genes play in rickettsial pathogenesis. The G8::lox mutant employed in this study contained a transposon insertion in the RPATATE_1142 gene which encodes an N-acetylmuramoyl-L-alanine amidase family protein. These enzymes are involved in cell wall breakdown and recycling, and therefore defects in bacterial cell wall integrity may have been involved in the attenuated mouse infection observed with this mutant; further investigation will be required to elucidate the function of this protein and its potential roles in <italic toggle="yes">R. parkeri</italic> biology. Although this mutant was not included in our preliminary analysis of mouse infectivity of transposon mutants, the low number of the G8::lox[virB9-mKate] mutant rickettsiae detected (only a few hundred copies compared with thousands of copies for a WT infection) in mice 3 dpi in the vaccination study indicated that it had reduced virulence in vivo. Moreover, the incorporation of GFPuv and rifampicin resistance on the transposon facilitated the detection and selection of mutants following successful RMCE to swap in the modified epitope arrays incorporating <italic toggle="yes">mKate</italic> and <italic toggle="yes">aadA</italic> codons.</p><p>One application of the RMCE approach, which we began to investigate in this study, is the introduction of epitope sequences from various tick-borne pathogens into the introduced cassette, turning an attenuated <italic toggle="yes">R. parkeri</italic> mutant into a multivalent live-attenuated vaccine that would confer immunity to SFG rickettsiae as well as the pathogens covered by the epitopes. By inserting an array of epitopes from multiple tick-borne pathogens in this way, a vaccine protective against a range of tick-borne diseases could be developed. Our collection of attenuated mutants represents a valuable pool for future vaccine studies when complemented using RMCE to express various epitopes from tick-borne pathogens. To test this approach, we incorporated epitope sequences from <italic toggle="yes">A. phagocytophilum</italic> proteins that have been identified as promising vaccine candidates. The <italic toggle="yes">Anaplasma</italic> surface proteins Asp55 and Asp62 were recognized by serum from an anaplasmosis patient, and anti-Asp55 and anti-Asp62 sera reduced infection of HL60 cells by <italic toggle="yes">A. phagocytophilum</italic> [<xref rid="B35-vaccines-13-00109" ref-type="bibr">35</xref>]. VirB9-1 is a component of the T4SS that has shown promise as a vaccine candidate against <italic toggle="yes">Anaplasma marginale</italic> infection in cattle [<xref rid="B34-vaccines-13-00109" ref-type="bibr">34</xref>,<xref rid="B37-vaccines-13-00109" ref-type="bibr">37</xref>]. However, cattle vaccinated with recombinant virB9-1, virB9-2, virB10, and virB11 were not protected against challenge with virulent <italic toggle="yes">A. marginale</italic>, despite mounting a specific antibody response to the antigens [<xref rid="B56-vaccines-13-00109" ref-type="bibr">56</xref>]. Similarly, although sera from mice vaccinated with recombinant virB9-1 and virB9-2 recognized corresponding proteins in <italic toggle="yes">A. phagocytophilum</italic>, the immunization was ineffective at preventing <italic toggle="yes">A. phagocytophilum</italic> infection in mice [<xref rid="B57-vaccines-13-00109" ref-type="bibr">57</xref>]. Likewise, we found that mice vaccinated with <italic toggle="yes">R. parkeri</italic> expressing a virB9-1 epitope failed to develop protective immunity against subsequent <italic toggle="yes">A. phagocytophilum</italic> infection, even though they generated antibodies that bound the pathogen. Further experimentation using different antigens and epitopes will be required to perfect this approach and determine whether it is feasible for generating a novel vaccine conferring broad protectivity against multiple tick-borne pathogens. It is appreciated that vaccines consisting of epitopes from multiple antigens confer better protection than vaccines based on a single antigen [<xref rid="B58-vaccines-13-00109" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-13-00109" ref-type="bibr">59</xref>]. Although our original plan was to include multiple antigenic epitopes, the expression of these arrays was difficult to achieve in <italic toggle="yes">R. parkeri</italic>, despite being successful in <italic toggle="yes">E. coli.</italic> Only virB9 and Asp62 were successfully expressed as mKate fusion proteins in <italic toggle="yes">R. parkeri,</italic> with differing strengths of expression. Similarly, the expression of mKate-epitope fusion proteins appeared to be low relative to GFPuv expression, which was transcribed from the same shuttle vector plasmid (see <xref rid="vaccines-13-00109-f006" ref-type="fig">Figure 6</xref>). Possibly, the expression of two fluorophores is energetically too demanding, as metabolic resources must be diverted to their production, or too toxic for the rickettsiae to be able to sustain. It has been shown that the production of fluorescent proteins induces H<sub>2</sub>O<sub>2</sub> that can damage cells and bacteria [<xref rid="B60-vaccines-13-00109" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-13-00109" ref-type="bibr">61</xref>]. We also noticed that the expression of mKate in these plasmid-transformed rickettsiae reduced over time, being lower in higher sub-passage <italic toggle="yes">R. parkeri</italic> transformants. Further modifications to the shuttle vector system to improve its stability, e.g., by using a less strong promoter, or its ability to incorporate large inserts could be attempted in the future. It is unclear why some epitopes or epitope combinations were not successfully expressed by transformed <italic toggle="yes">R. parkeri.</italic> The optimization of epitopes, for example codon optimization to improve expression, may be required for them to be expressed successfully in this pathogen. However, codon usage in AT-rich bacteria including the Rickettsiales is similar, favoring U or A in the first and third positions [<xref rid="B62-vaccines-13-00109" ref-type="bibr">62</xref>].</p><p>Although we did not further investigate the effects of epitope arrays containing the YchF epitope, the negative outcomes were unexpected. The YchF sequences (from a gene encoding a ribosome-binding ATPase) were included in the hope of enhancing the expression of arrays, but its puzzling effect on mouse mortality prompted us to search the literature for a possible explanation. Considering the body weight data showing that YchF-immunized mice did not recover following challenge (<xref rid="vaccines-13-00109-f004" ref-type="fig">Figure 4</xref>A), we concluded that immunization against rickettsial YchF proved deleterious for mice. Epitopes from this protein were included because of its presumptive role as an ATPase that binds to both the 70S ribosome and the 50S ribosomal subunit. However, research indicates that it is a highly conserved negative regulator of the oxidative stress response in both bacteria and eukaryotes [<xref rid="B49-vaccines-13-00109" ref-type="bibr">49</xref>,<xref rid="B63-vaccines-13-00109" ref-type="bibr">63</xref>], which is an important pathogenicity mechanism of rickettsiae. Whilst the overexpression of YchF has been shown to reduce resistance to stress in <italic toggle="yes">E. coli</italic>, plants, and human cells [<xref rid="B49-vaccines-13-00109" ref-type="bibr">49</xref>,<xref rid="B63-vaccines-13-00109" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-13-00109" ref-type="bibr">64</xref>], the deletion of the gene in the bacteria <italic toggle="yes">Vibrio vulnificus</italic> and <italic toggle="yes">Streptococcus pneumoniae</italic> reduced virulence in mice [<xref rid="B65-vaccines-13-00109" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00109" ref-type="bibr">66</xref>]. In <italic toggle="yes">V. vulnificus</italic>, deleting <italic toggle="yes">ychF</italic> was linked to the reduced transcription of the virulence factor RtxA1 toxin [<xref rid="B65-vaccines-13-00109" ref-type="bibr">65</xref>]; therefore, the overexpression of a portion of YchF in <italic toggle="yes">R. parkeri</italic> could potentially increase its mouse infectivity through an increased transcription of virulence factors. However, since the portion of YchF used as the epitope in this study did not contain its catalytic site, this seems unlikely. An alternative explanation, which might arise due to the highly conserved nature of this protein across bacteria and eukaryotes [<xref rid="B67-vaccines-13-00109" ref-type="bibr">67</xref>], is that the epitope induced auto-immunity against the murine YchF homolog, which may cause increased mortality. Further research into the roles of YchF in <italic toggle="yes">R. parkeri</italic> virulence would be interesting and could shed light on our observed results.</p><p>Building on previous successes in transposon mutagenesis, this research has developed a genetic tool for the exchange of the inserted transposon with a cassette containing genes of interest, which can be applied to the study of gene function in rickettsiae. The potential for the use of this method in other areas, such as the analysis of gene function, non-coding RNAs, promoters, and regulatory elements, will also benefit the field. Although our attempts to apply this method to the generation of a novel attenuated vaccine were unsuccessful, this remains a promising use of this technology that could be further explored after the identification of effective antigens and optimization of their epitopes for expression in <italic toggle="yes">R. parkeri.</italic></p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Samuel Swanson, Westley Timmerman, and Anna Prohofsky for animal care during this project.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00109"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020109/s1">https://www.mdpi.com/article/10.3390/vaccines13020109/s1</uri>, Figure S1: Reactivity of epitope-immunized mouse sera to <italic toggle="yes">A. phagocytophilum</italic> and recombinant peptides; Figure S2: Transcription of epitope arrays in plasmid-transformed <italic toggle="yes">R. parkeri</italic>; Figure S3: Persistence of vaccine strain <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] in mice; Table S1: List of primers used in the study; Table S2: List of transposon mutants generated; Table S3: Densitometry data from Western blots.</p><supplementary-material id="vaccines-13-00109-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00109-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, B.C., J.D.O., N.Y.B., R.F. and U.G.M.; methodology, B.C., J.D.O., N.Y.B. and U.G.M.; validation, B.C., N.Y.B. and U.G.M.; formal analysis, B.C., B.S.K., K.K. and U.G.M.; investigation, B.C., B.S.K., J.D.O., L.D.P., K.K., N.Y.B. and X.-R.W.; data curation, B.C., B.S.K., L.D.P., N.Y.B. and X.-R.W.; writing&#x02014;original draft preparation, B.C. and U.G.M.; writing&#x02014;review and editing, B.C., B.S.K., J.D.O., N.Y.B., R.F., U.G.M. and X.W; visualization, B.C., N.Y.B. and X.-R.W.; supervision, R.F. and U.G.M.; project administration, B.C., J.D.O. and U.G.M.; funding acquisition, R.F. and U.G.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the University of Minnesota Institutional Animal Care and Use Committee and Institutional Biosafety Committee (protocol 2105-39122H).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-vaccines-13-00109" ref-type="app">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding author(s).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00109"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blanton</surname><given-names>L.S.</given-names></name>
</person-group><article-title>The Rickettsioses: A Practical Update</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2019</year><volume>33</volume><fpage>213</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2018.10.010</pub-id><pub-id pub-id-type="pmid">30712763</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00109"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Binder</surname><given-names>A.M.</given-names></name>
<name><surname>Nichols Heitman</surname><given-names>K.</given-names></name>
<name><surname>Drexler</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Diagnostic Methods Used to Classify Confirmed and Probable Cases of Spotted Fever Rickettsioses&#x02014;United States, 2010&#x02013;2015</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2019</year><volume>68</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6810a3</pub-id><pub-id pub-id-type="pmid">30870409</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00109"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osterloh</surname><given-names>A.</given-names></name>
</person-group><article-title>The Neglected Challenge: Vaccination against Rickettsiae</article-title><source>PLoS Negl. Trop. Dis.</source><year>2020</year><volume>14</volume><elocation-id>e0008704</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0008704</pub-id><pub-id pub-id-type="pmid">33091016</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00109"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>A.</given-names></name>
<name><surname>Tucker</surname><given-names>A.M.</given-names></name>
<name><surname>Hines</surname><given-names>A.</given-names></name>
<name><surname>Wood</surname><given-names>D.O.</given-names></name>
</person-group><article-title>Transposon Mutagenesis of the Obligate Intracellular Pathogen <italic toggle="yes">Rickettsia prowazekii</italic></article-title><source>Appl. Environ. Microbiol.</source><year>2004</year><volume>70</volume><fpage>2816</fpage><lpage>2822</lpage><pub-id pub-id-type="doi">10.1128/AEM.70.5.2816-2822.2004</pub-id><pub-id pub-id-type="pmid">15128537</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00109"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noriea</surname><given-names>N.F.</given-names></name>
<name><surname>Clark</surname><given-names>T.R.</given-names></name>
<name><surname>Hackstadt</surname><given-names>T.</given-names></name>
</person-group><article-title>Targeted Knockout of the <italic toggle="yes">Rickettsia rickettsii</italic> OmpA Surface Antigen Does Not Diminish Virulence in a Mammalian Model System</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e00323-15</fpage><pub-id pub-id-type="doi">10.1128/mBio.00323-15</pub-id><pub-id pub-id-type="pmid">25827414</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00109"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arroyave</surname><given-names>E.</given-names></name>
<name><surname>Hyseni</surname><given-names>I.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.</given-names></name>
<name><surname>Kuo</surname><given-names>Y.-F.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.</given-names></name>
<name><surname>Fang</surname><given-names>R.</given-names></name>
</person-group><article-title><italic toggle="yes">Rickettsia parkeri</italic> with a Genetically Disrupted Phage Integrase Gene Exhibits Attenuated Virulence and Induces Protective Immunity against Fatal Rickettsioses in Mice</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>819</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10070819</pub-id><pub-id pub-id-type="pmid">34208806</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00109"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osterloh</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccine Design and Vaccination Strategies against Rickettsiae</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>896</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9080896</pub-id><pub-id pub-id-type="pmid">34452021</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00109"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>D.H.</given-names></name>
<name><surname>Blanton</surname><given-names>L.S.</given-names></name>
<name><surname>Laroche</surname><given-names>M.</given-names></name>
<name><surname>Fang</surname><given-names>R.</given-names></name>
<name><surname>Narra</surname><given-names>H.P.</given-names></name>
</person-group><article-title>A Vaccine for Canine Rocky Mountain Spotted Fever: An Unmet One Health Need</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1626</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10101626</pub-id><pub-id pub-id-type="pmid">36298491</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00109"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Conor</surname><given-names>M.C.</given-names></name>
<name><surname>Herron</surname><given-names>M.J.</given-names></name>
<name><surname>Nelson</surname><given-names>C.M.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
<name><surname>Crosby</surname><given-names>F.L.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Price</surname><given-names>L.D.</given-names></name>
<name><surname>Brayton</surname><given-names>K.A.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title>Biostatistical Prediction of Genes Essential for Growth of <italic toggle="yes">Anaplasma phagocytophilum</italic> in a Human Promyelocytic Cell Line Using a Random Transposon Mutant Library</article-title><source>Pathog. Dis.</source><year>2021</year><volume>79</volume><fpage>ftab029</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftab029</pub-id><pub-id pub-id-type="pmid">34077527</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00109"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamason</surname><given-names>R.L.</given-names></name>
<name><surname>Bastounis</surname><given-names>E.</given-names></name>
<name><surname>Kafai</surname><given-names>N.M.</given-names></name>
<name><surname>Serrano</surname><given-names>R.</given-names></name>
<name><surname>del &#x000c1;lamo</surname><given-names>J.C.</given-names></name>
<name><surname>Theriot</surname><given-names>J.A.</given-names></name>
<name><surname>Welch</surname><given-names>M.D.</given-names></name>
</person-group><article-title><italic toggle="yes">Rickettsia</italic> Sca4 Reduces Vinculin-Mediated Intercellular Tension to Promote Spread</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>670</fpage><lpage>683.e10</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.023</pub-id><pub-id pub-id-type="pmid">27768890</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00109"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blanton</surname><given-names>L.S.</given-names></name>
<name><surname>Mendell</surname><given-names>N.L.</given-names></name>
<name><surname>Walker</surname><given-names>D.H.</given-names></name>
<name><surname>Bouyer</surname><given-names>D.H.</given-names></name>
</person-group><article-title>&#x0201c;<italic toggle="yes">Rickettsia amblyommii</italic>&#x0201d; Induces Cross Protection Against Lethal Rocky Mountain Spotted Fever in a Guinea Pig Model</article-title><source>Vector-Borne Zoonotic Dis.</source><year>2014</year><volume>14</volume><fpage>557</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1089/vbz.2014.1575</pub-id><pub-id pub-id-type="pmid">25072985</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00109"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>W.C.</given-names></name>
<name><surname>Waner</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Serological Cross-Reaction and Cross-Protection in Guinea Pigs Infected with <italic toggle="yes">Rickettsia rickettsii</italic> and <italic toggle="yes">Rickettsia montana</italic></article-title><source>Infect. Immun.</source><year>1980</year><volume>28</volume><fpage>627</fpage><pub-id pub-id-type="doi">10.1128/iai.28.2.627-629.1980</pub-id><pub-id pub-id-type="pmid">6893191</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00109"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>H.</given-names></name>
<name><surname>Walker</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Cross-Protection between Distantly Related Spotted Fever Group Rickettsiae</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>3901</fpage><lpage>3905</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00301-3</pub-id><pub-id pub-id-type="pmid">12922124</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00109"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Baldridge</surname><given-names>G.D.</given-names></name>
<name><surname>Williamson</surname><given-names>P.C.</given-names></name>
<name><surname>Billingsley</surname><given-names>P.M.</given-names></name>
<name><surname>Heu</surname><given-names>C.C.</given-names></name>
<name><surname>Felsheim</surname><given-names>R.F.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title>Development of Shuttle Vectors for Transformation of Diverse <italic toggle="yes">Rickettsia</italic> Species</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e29511</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029511</pub-id><pub-id pub-id-type="pmid">22216299</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00109"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Araki</surname><given-names>K.</given-names></name>
</person-group><article-title>Site-Directed Integration of the Cre Gene Mediated by Cre Recombinase Using a Combination of Mutant Lox Sites</article-title><source>Nucleic Acids Res.</source><year>2002</year><volume>30</volume><fpage>e103</fpage><pub-id pub-id-type="doi">10.1093/nar/gnf102</pub-id><pub-id pub-id-type="pmid">12364620</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00109"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schudel</surname><given-names>S.</given-names></name>
<name><surname>Gygax</surname><given-names>L.</given-names></name>
<name><surname>Kositz</surname><given-names>C.</given-names></name>
<name><surname>Kuenzli</surname><given-names>E.</given-names></name>
<name><surname>Neumayr</surname><given-names>A.</given-names></name>
</person-group><article-title>Human Granulocytotropic Anaplasmosis&#x02014;A Systematic Review and Analysis of the Literature</article-title><source>PLoS Negl. Trop. Dis.</source><year>2024</year><volume>18</volume><elocation-id>e0012313</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0012313</pub-id><pub-id pub-id-type="pmid">39102427</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00109"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dumler</surname><given-names>J.S.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
<name><surname>Bekker</surname><given-names>C.P.</given-names></name>
<name><surname>Dasch</surname><given-names>G.A.</given-names></name>
<name><surname>Palmer</surname><given-names>G.H.</given-names></name>
<name><surname>Ray</surname><given-names>S.C.</given-names></name>
<name><surname>Rikihisa</surname><given-names>Y.</given-names></name>
<name><surname>Rurangirwa</surname><given-names>F.R.</given-names></name>
</person-group><article-title>Reorganization of Genera in the Families Rickettsiaceae and Anaplasmataceae in the Order Rickettsiales: Unification of Some Species of <italic toggle="yes">Ehrlichia</italic> with <italic toggle="yes">Anaplasma, Cowdria</italic> with <italic toggle="yes">Ehrlichia</italic> and <italic toggle="yes">Ehrlichia</italic> with <italic toggle="yes">Neorickettsia</italic>, Descriptions of Six New Species Combinations and designation of <italic toggle="yes">Ehrlichia equi</italic> and &#x02019;HGE agent&#x02019; as subjective synonyms of <italic toggle="yes">Ehrlichia phagocytophila</italic></article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2001</year><volume>51</volume><fpage>2145</fpage><lpage>2165</lpage><pub-id pub-id-type="pmid">11760958</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00109"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paddock</surname><given-names>C.D.</given-names></name>
<name><surname>Fournier</surname><given-names>P.-E.</given-names></name>
<name><surname>Sumner</surname><given-names>J.W.</given-names></name>
<name><surname>Goddard</surname><given-names>J.</given-names></name>
<name><surname>Elshenawy</surname><given-names>Y.</given-names></name>
<name><surname>Metcalfe</surname><given-names>M.G.</given-names></name>
<name><surname>Loftis</surname><given-names>A.D.</given-names></name>
<name><surname>Varela-Stokes</surname><given-names>A.</given-names></name>
</person-group><article-title>Isolation of <italic toggle="yes">Rickettsia parkeri</italic> and Identification of a Novel Spotted Fever Group Rickettsia Sp. from Gulf Coast Ticks (<italic toggle="yes">Amblyomma maculatum</italic>) in the United States</article-title><source>Appl. Environ. Microbiol.</source><year>2010</year><volume>76</volume><fpage>2689</fpage><lpage>2696</lpage><pub-id pub-id-type="doi">10.1128/AEM.02737-09</pub-id><pub-id pub-id-type="pmid">20208020</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00109"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.R.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Price</surname><given-names>L.D.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title>An Electroporation Method to Transform <italic toggle="yes">Rickettsia</italic> Spp. with a Fluorescent Protein-Expressing Shuttle Vector in Tick Cell Lines</article-title><source>J. Vis. Exp.</source><year>2022</year><volume>2022</volume><fpage>e64562</fpage><pub-id pub-id-type="doi">10.3791/64562</pub-id></element-citation></ref><ref id="B20-vaccines-13-00109"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodman</surname><given-names>J.L.</given-names></name>
<name><surname>Nelson</surname><given-names>C.</given-names></name>
<name><surname>Vitale</surname><given-names>B.</given-names></name>
<name><surname>Madigan</surname><given-names>J.E.</given-names></name>
<name><surname>Dumler</surname><given-names>J.S.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title>Direct Cultivation of the Causative Agent of Human Granulocytic Ehrlichiosis</article-title><source>N. Engl. J. Med.</source><year>1996</year><volume>334</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1056/NEJM199601253340401</pub-id><pub-id pub-id-type="pmid">8531996</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00109"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Felsheim</surname><given-names>R.F.</given-names></name>
<name><surname>Herron</surname><given-names>M.J.</given-names></name>
<name><surname>Nelson</surname><given-names>C.M.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title>Transformation of <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>BMC Biotechnol.</source><year>2006</year><volume>6</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-6-42</pub-id><pub-id pub-id-type="pmid">17076894</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00109"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>C.</given-names></name>
<name><surname>Nair</surname><given-names>A.D.S.</given-names></name>
<name><surname>Indukuri</surname><given-names>V.V.</given-names></name>
<name><surname>Gong</surname><given-names>S.</given-names></name>
<name><surname>Felsheim</surname><given-names>R.F.</given-names></name>
<name><surname>Jaworski</surname><given-names>D.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<name><surname>Ganta</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Targeted and Random Mutagenesis of <italic toggle="yes">Ehrlichia chaffeensis</italic> for the Identification of Genes Required for In Vivo Infection</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003171</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/322c8bba-8dae-4196-b85d-5de315e44d76</pub-id><pub-id pub-id-type="pmid">23459099</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00109"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
<name><surname>Meeus</surname><given-names>P.F.M.</given-names></name>
<name><surname>B&#x000e9;langer</surname><given-names>M.</given-names></name>
<name><surname>Bowie</surname><given-names>M.V.</given-names></name>
<name><surname>Yi</surname><given-names>J.</given-names></name>
<name><surname>Lundgren</surname><given-names>A.M.</given-names></name>
<name><surname>Alleman</surname><given-names>A.R.</given-names></name>
<name><surname>Wong</surname><given-names>S.J.</given-names></name>
<name><surname>Chu</surname><given-names>F.K.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<etal/>
</person-group><article-title>Expression of Multiple Outer Membrane Protein Sequence Variants from a Single Genomic Locus of <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>1706</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.4.1706-1718.2003</pub-id><pub-id pub-id-type="pmid">12654783</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00109"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z.-M.</given-names></name>
<name><surname>Tucker</surname><given-names>A.M.</given-names></name>
<name><surname>Driskell</surname><given-names>L.O.</given-names></name>
<name><surname>Wood</surname><given-names>D.O.</given-names></name>
</person-group><article-title><italic toggle="yes">Mariner</italic>-Based Transposon Mutagenesis of <italic toggle="yes">Rickettsia prowazekii</italic></article-title><source>Appl. Environ. Microbiol.</source><year>2007</year><volume>73</volume><fpage>6644</fpage><lpage>6649</lpage><pub-id pub-id-type="doi">10.1128/AEM.01727-07</pub-id><pub-id pub-id-type="pmid">17720821</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00109"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Dyachenko</surname><given-names>V.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<name><surname>Straubinger</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Transmission of <italic toggle="yes">Anaplasma phagocytophilum</italic> from Endothelial Cells to Peripheral Granulocytes in Vitro under Shear Flow Conditions</article-title><source>Med. Microbiol. Immunol.</source><year>2015</year><volume>204</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1007/s00430-015-0387-0</pub-id><pub-id pub-id-type="pmid">25618174</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00109"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lynn</surname><given-names>G.E.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Felsheim</surname><given-names>R.F.</given-names></name>
<name><surname>Nelson</surname><given-names>C.M.</given-names></name>
<name><surname>Oliver</surname><given-names>J.D.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Cornax</surname><given-names>I.</given-names></name>
<name><surname>O&#x02019;Sullivan</surname><given-names>M.G.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
</person-group><article-title><italic toggle="yes">Ehrlichia</italic> Isolate from a Minnesota Tick: Characterization and Genetic Transformation</article-title><source>Appl. Environ. Microbiol.</source><year>2019</year><volume>85</volume><fpage>e00866-19</fpage><pub-id pub-id-type="doi">10.1128/AEM.00866-19</pub-id><pub-id pub-id-type="pmid">31076433</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00109"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eisemann</surname><given-names>C.S.</given-names></name>
<name><surname>Nypaver</surname><given-names>M.J.</given-names></name>
<name><surname>Osterman</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Susceptibility of Inbred Mice to Rickettsiae of the Spotted Fever Group</article-title><source>Infect. Immun.</source><year>1984</year><volume>43</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1128/iai.43.1.143-148.1984</pub-id><pub-id pub-id-type="pmid">6418657</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00109"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grasperge</surname><given-names>B.J.</given-names></name>
<name><surname>Reif</surname><given-names>K.E.</given-names></name>
<name><surname>Morgan</surname><given-names>T.D.</given-names></name>
<name><surname>Sunyakumthorn</surname><given-names>P.</given-names></name>
<name><surname>Bynog</surname><given-names>J.</given-names></name>
<name><surname>Paddock</surname><given-names>C.D.</given-names></name>
<name><surname>Macaluso</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Susceptibility of Inbred Mice to <italic toggle="yes">Rickettsia parkeri</italic></article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>1846</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1128/IAI.00109-12</pub-id><pub-id pub-id-type="pmid">22392926</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00109"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodzic</surname><given-names>E.</given-names></name>
<name><surname>IJdo</surname><given-names>J.W.I.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
<name><surname>Katavolos</surname><given-names>P.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Maretzki</surname><given-names>C.H.</given-names></name>
<name><surname>Fish</surname><given-names>D.</given-names></name>
<name><surname>Fikrig</surname><given-names>E.</given-names></name>
<name><surname>Telford</surname><given-names>S.R.</given-names><suffix>III</suffix></name>
<name><surname>Barthold</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Granulocytic Ehrlichiosis in the Laboratory Mouse</article-title><source>J. Infect. Dis.</source><year>1998</year><volume>177</volume><fpage>737</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1086/514236</pub-id><pub-id pub-id-type="pmid">9498456</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00109"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>M.E.</given-names></name>
<name><surname>Bunnell</surname><given-names>J.E.</given-names></name>
<name><surname>Dumler</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Pathology, Immunohistology, and Cytokine Responses in Early Phases of Human Granulocytic Ehrlichiosis in a Murine Model</article-title><source>J. Infect. Dis.</source><year>2000</year><volume>181</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1086/315206</pub-id><pub-id pub-id-type="pmid">10608792</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00109"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stenos</surname><given-names>J.</given-names></name>
<name><surname>Graves</surname><given-names>S.R.</given-names></name>
<name><surname>Unsworth</surname><given-names>N.B.</given-names></name>
</person-group><article-title>A Highly Sensitive and Specific Real-Time PCR Assay for the Detection of Spotted Fever and Typhus Group Rickettsiae</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2005</year><volume>73</volume><fpage>1083</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2005.73.1083</pub-id><pub-id pub-id-type="pmid">16354816</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00109"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hagen</surname><given-names>R.</given-names></name>
<name><surname>Verhoeve</surname><given-names>V.I.</given-names></name>
<name><surname>Gillespie</surname><given-names>J.J.</given-names></name>
<name><surname>Driscoll</surname><given-names>T.P.</given-names></name>
</person-group><article-title>Conjugative Transposons and Their Cargo Genes Vary across Natural Populations of <italic toggle="yes">Rickettsia buchneri</italic> Infecting the Tick <italic toggle="yes">Ixodes scapularis</italic></article-title><source>Genome Biol. Evol.</source><year>2018</year><volume>10</volume><fpage>3218</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1093/gbe/evy247</pub-id><pub-id pub-id-type="pmid">30398619</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00109"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sutten</surname><given-names>E.L.</given-names></name>
<name><surname>Norimine</surname><given-names>J.</given-names></name>
<name><surname>Beare</surname><given-names>P.A.</given-names></name>
<name><surname>Heinzen</surname><given-names>R.A.</given-names></name>
<name><surname>Lopez</surname><given-names>J.E.</given-names></name>
<name><surname>Morse</surname><given-names>K.</given-names></name>
<name><surname>Brayton</surname><given-names>K.A.</given-names></name>
<name><surname>Gillespie</surname><given-names>J.J.</given-names></name>
<name><surname>Brown</surname><given-names>W.C.</given-names></name>
</person-group><article-title><italic toggle="yes">Anaplasma marginale</italic> Type IV Secretion System Proteins VirB2, VirB7, VirB11, and VirD4 Are Immunogenic Components of a Protective Bacterial Membrane Vaccine</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>1314</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1128/IAI.01207-09</pub-id><pub-id pub-id-type="pmid">20065028</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00109"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Mahony</surname><given-names>D.</given-names></name>
<name><surname>Cavallaro</surname><given-names>A.S.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Deringer</surname><given-names>J.R.</given-names></name>
<name><surname>Zhao</surname><given-names>C.X.</given-names></name>
<name><surname>Brown</surname><given-names>W.C.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Mitter</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of Outer Membrane Proteins VirB9-1 and VirB9-2, a Novel Nanovaccine against <italic toggle="yes">Anaplasma marginale</italic></article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0154295</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154295</pub-id><pub-id pub-id-type="pmid">27115492</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00109"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y.</given-names></name>
<name><surname>Rikihisa</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identification of Novel Surface Proteins of <italic toggle="yes">Anaplasma phagocytophilum</italic> by Affinity Purification and Proteomics</article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>7819</fpage><lpage>7828</lpage><pub-id pub-id-type="doi">10.1128/JB.00866-07</pub-id><pub-id pub-id-type="pmid">17766422</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00109"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Khedery</surname><given-names>B.</given-names></name>
<name><surname>Lundgren</surname><given-names>A.M.</given-names></name>
<name><surname>Stuen</surname><given-names>S.</given-names></name>
<name><surname>Granquist</surname><given-names>E.G.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<name><surname>Nelson</surname><given-names>C.M.</given-names></name>
<name><surname>Alleman</surname><given-names>A.R.</given-names></name>
<name><surname>Mahan</surname><given-names>S.M.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Structure of the Type IV Secretion System in Different Strains of <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>BMC Genom.</source><year>2012</year><volume>13</volume><elocation-id>678</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-13-678</pub-id><pub-id pub-id-type="pmid">23190684</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00109"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>J.E.</given-names></name>
<name><surname>Palmer</surname><given-names>G.H.</given-names></name>
<name><surname>Brayton</surname><given-names>K.A.</given-names></name>
<name><surname>Dark</surname><given-names>M.J.</given-names></name>
<name><surname>Leach</surname><given-names>S.E.</given-names></name>
<name><surname>Brown</surname><given-names>W.C.</given-names></name>
</person-group><article-title>Immunogenicity of <italic toggle="yes">Anaplasma marginale</italic> Type IV Secretion System Proteins in a Protective Outer Membrane Vaccine</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>2333</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1128/IAI.00061-07</pub-id><pub-id pub-id-type="pmid">17339347</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00109"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jespersen</surname><given-names>M.C.</given-names></name>
<name><surname>Peters</surname><given-names>B.</given-names></name>
<name><surname>Nielsen</surname><given-names>M.</given-names></name>
<name><surname>Marcatili</surname><given-names>P.</given-names></name>
</person-group><article-title>BepiPred-2.0: Improving Sequence-Based B-Cell Epitope Prediction Using Conformational Epitopes</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W24</fpage><lpage>W29</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id><pub-id pub-id-type="pmid">28472356</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00109"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parker</surname><given-names>J.M.R.</given-names></name>
<name><surname>Guo</surname><given-names>D.</given-names></name>
<name><surname>Hodges</surname><given-names>R.S.</given-names></name>
</person-group><article-title>New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and x-Ray-Derived Accessible Sites</article-title><source>Biochemistry</source><year>1986</year><volume>25</volume><fpage>5425</fpage><lpage>5432</lpage><pub-id pub-id-type="doi">10.1021/bi00367a013</pub-id><pub-id pub-id-type="pmid">2430611</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00109"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kolaskar</surname><given-names>A.S.</given-names></name>
<name><surname>Tongaonkar</surname><given-names>P.C.</given-names></name>
</person-group><article-title>A Semi-empirical Method for Prediction of Antigenic Determinants on Protein Antigens</article-title><source>FEBS Lett.</source><year>1990</year><volume>276</volume><fpage>172</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(90)80535-Q</pub-id><pub-id pub-id-type="pmid">1702393</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00109"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karplus</surname><given-names>P.A.</given-names></name>
<name><surname>Schulz</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Prediction of Chain Flexibility in Proteins</article-title><source>Naturwissenschaften</source><year>1985</year><volume>72</volume><fpage>212</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1007/BF01195768</pub-id></element-citation></ref><ref id="B42-vaccines-13-00109"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emini</surname><given-names>E.A.</given-names></name>
<name><surname>Hughes</surname><given-names>J.V.</given-names></name>
<name><surname>Perlow</surname><given-names>D.S.</given-names></name>
<name><surname>Boger</surname><given-names>J.</given-names></name>
</person-group><article-title>Induction of Hepatitis A Virus-Neutralizing Antibody by a Virus-Specific Synthetic Peptide</article-title><source>J. Virol.</source><year>1985</year><volume>55</volume><fpage>836</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1128/jvi.55.3.836-839.1985</pub-id><pub-id pub-id-type="pmid">2991600</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00109"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chou</surname><given-names>P.Y.</given-names></name>
<name><surname>Fasman</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Prediction of the Secondary Structure of Proteins from Their Amino Acid Sequence</article-title><source>Adv. Enzymol. Relat. Areas Mol. Biol.</source><year>1978</year><volume>47</volume><fpage>45</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1002/9780470122921.ch2</pub-id><pub-id pub-id-type="pmid">364941</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00109"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>ThermoFisher Scientific</collab>
</person-group><source>Extract Proteins from Polyacrylamide Gels</source><publisher-name>ThermoFisher Scientific</publisher-name><publisher-loc>Waltham, MA, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B45-vaccines-13-00109"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bunnell</surname><given-names>J.E.</given-names></name>
<name><surname>Trigiani</surname><given-names>E.R.</given-names></name>
<name><surname>Srinivas</surname><given-names>S.R.</given-names></name>
<name><surname>Dumler</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Development and Distribution of Pathologic Lesions Are Related to Immune Status and Tissue Deposition of Human Granulocytic Ehrlichiosis Agent&#x02013;Infected Cells in a Murine Model System</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>180</volume><fpage>546</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1086/314902</pub-id><pub-id pub-id-type="pmid">10395880</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00109"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliva Ch&#x000e1;vez</surname><given-names>A.S.</given-names></name>
<name><surname>Fairman</surname><given-names>J.W.</given-names></name>
<name><surname>Felsheim</surname><given-names>R.F.</given-names></name>
<name><surname>Nelson</surname><given-names>C.M.</given-names></name>
<name><surname>Herron</surname><given-names>M.J.</given-names></name>
<name><surname>Higgins</surname><given-names>L.A.</given-names></name>
<name><surname>Burkhardt</surname><given-names>N.Y.</given-names></name>
<name><surname>Oliver</surname><given-names>J.D.</given-names></name>
<name><surname>Markowski</surname><given-names>T.W.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<etal/>
</person-group><article-title>An O-Methyltransferase Is Required for Infection of Tick Cells by <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005248</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005248</pub-id><pub-id pub-id-type="pmid">26544981</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00109"><label>47.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Carlyon</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Laboratory Maintenance of <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>Current Protocols in Microbiology</source><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2005</year><volume>Volume 3</volume><fpage>3A.2.1</fpage><lpage>3A.2.30</lpage></element-citation></ref><ref id="B48-vaccines-13-00109"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laukaitis</surname><given-names>H.J.</given-names></name>
<name><surname>Cooper</surname><given-names>T.T.</given-names></name>
<name><surname>Suwanbongkot</surname><given-names>C.</given-names></name>
<name><surname>Verhoeve</surname><given-names>V.I.</given-names></name>
<name><surname>Kurtti</surname><given-names>T.J.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<name><surname>Macaluso</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Transposon Mutagenesis of <italic toggle="yes">Rickettsia felis</italic> Sca1 Confers a Distinct Phenotype during Flea Infection</article-title><source>PLOS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1011045</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011045</pub-id><pub-id pub-id-type="pmid">36542675</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00109"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wenk</surname><given-names>M.</given-names></name>
<name><surname>Ba</surname><given-names>Q.</given-names></name>
<name><surname>Erichsen</surname><given-names>V.</given-names></name>
<name><surname>MacInnes</surname><given-names>K.</given-names></name>
<name><surname>Wiese</surname><given-names>H.</given-names></name>
<name><surname>Warscheid</surname><given-names>B.</given-names></name>
<name><surname>Koch</surname><given-names>H.G.</given-names></name>
</person-group><article-title>A Universally Conserved ATPase Regulates the Oxidative Stress Response in <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>43585</fpage><lpage>43598</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.413070</pub-id><pub-id pub-id-type="pmid">23139412</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00109"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClure</surname><given-names>E.E.</given-names></name>
<name><surname>Ch&#x000e1;vez</surname><given-names>A.S.O.</given-names></name>
<name><surname>Shaw</surname><given-names>D.K.</given-names></name>
<name><surname>Carlyon</surname><given-names>J.A.</given-names></name>
<name><surname>Ganta</surname><given-names>R.R.</given-names></name>
<name><surname>Noh</surname><given-names>S.M.</given-names></name>
<name><surname>Wood</surname><given-names>D.O.</given-names></name>
<name><surname>Bavoil</surname><given-names>P.M.</given-names></name>
<name><surname>Brayton</surname><given-names>K.A.</given-names></name>
<name><surname>Martinez</surname><given-names>J.J.</given-names></name>
<etal/>
</person-group><article-title>Engineering of Obligate Intracellular Bacteria: Progress, Challenges and Paradigms</article-title><source>Nat. Rev. Microbiol.</source><year>2017</year><volume>15</volume><fpage>544</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.59</pub-id><pub-id pub-id-type="pmid">28626230</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00109"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crosby</surname><given-names>F.L.</given-names></name>
<name><surname>Wamsley</surname><given-names>H.L.</given-names></name>
<name><surname>Pate</surname><given-names>M.G.</given-names></name>
<name><surname>Lundgren</surname><given-names>A.M.</given-names></name>
<name><surname>Noh</surname><given-names>S.M.</given-names></name>
<name><surname>Munderloh</surname><given-names>U.G.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Knockout of an Outer Membrane Protein Operon of <italic toggle="yes">Anaplasma marginale</italic> by Transposon Mutagenesis</article-title><source>BMC Genom.</source><year>2014</year><volume>15</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-278</pub-id></element-citation></ref><ref id="B52-vaccines-13-00109"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamason</surname><given-names>R.L.</given-names></name>
<name><surname>Kafai</surname><given-names>N.M.</given-names></name>
<name><surname>Welch</surname><given-names>M.D.</given-names></name>
</person-group><article-title>A Streamlined Method for Transposon Mutagenesis of <italic toggle="yes">Rickettsia parkeri</italic> Yields Numerous Mutations That Impact Infection</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0197012</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0197012</pub-id><pub-id pub-id-type="pmid">29723287</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00109"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGinn</surname><given-names>J.</given-names></name>
<name><surname>Wen</surname><given-names>A.</given-names></name>
<name><surname>Edwards</surname><given-names>D.L.</given-names></name>
<name><surname>Brinkley</surname><given-names>D.M.</given-names></name>
<name><surname>Lamason</surname><given-names>R.L.</given-names></name>
</person-group><article-title>An Expanded Genetic Toolkit for Inducible Expression and Targeted Gene Silencing in <italic toggle="yes">Rickettsia parkeri</italic></article-title><source>J. Bacteriol.</source><year>2024</year><volume>206</volume><fpage>e00091-24</fpage><pub-id pub-id-type="doi">10.1128/jb.00091-24</pub-id><pub-id pub-id-type="pmid">38842342</pub-id>
</element-citation></ref><ref id="B54-vaccines-13-00109"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nock</surname><given-names>A.M.</given-names></name>
<name><surname>Clark</surname><given-names>T.R.</given-names></name>
<name><surname>Hackstadt</surname><given-names>T.</given-names></name>
</person-group><article-title>Development of Inducible Promoter and CRISPRi Plasmids Functional in <italic toggle="yes">Rickettsia rickettsii</italic></article-title><source>J. Bacteriol.</source><year>2024</year><volume>206</volume><fpage>e00367-24</fpage><pub-id pub-id-type="doi">10.1128/jb.00367-24</pub-id><pub-id pub-id-type="pmid">39347571</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00109"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Engstr&#x000f6;m</surname><given-names>P.</given-names></name>
<name><surname>Burke</surname><given-names>T.P.</given-names></name>
<name><surname>Mitchell</surname><given-names>G.</given-names></name>
<name><surname>Ingabire</surname><given-names>N.</given-names></name>
<name><surname>Mark</surname><given-names>K.G.</given-names></name>
<name><surname>Golovkine</surname><given-names>G.</given-names></name>
<name><surname>Iavarone</surname><given-names>A.T.</given-names></name>
<name><surname>Rape</surname><given-names>M.</given-names></name>
<name><surname>Cox</surname><given-names>J.S.</given-names></name>
<name><surname>Welch</surname><given-names>M.D.</given-names></name>
</person-group><article-title>Evasion of Autophagy Mediated by <italic toggle="yes">Rickettsia</italic> Surface Protein OmpB Is Critical for Virulence</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>2538</fpage><lpage>2551</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0583-6</pub-id><pub-id pub-id-type="pmid">31611642</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00109"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarli</surname><given-names>M.</given-names></name>
<name><surname>Novoa</surname><given-names>M.B.</given-names></name>
<name><surname>Mazzucco</surname><given-names>M.N.</given-names></name>
<name><surname>Signorini</surname><given-names>M.L.</given-names></name>
<name><surname>Echaide</surname><given-names>I.E.</given-names></name>
<name><surname>de Echaide</surname><given-names>S.T.</given-names></name>
<name><surname>Primo</surname><given-names>M.E.</given-names></name>
</person-group><article-title>A Vaccine Using <italic toggle="yes">Anaplasma marginale</italic> Subdominant Type IV Secretion System Recombinant Proteins Was Not Protective against a Virulent Challenge</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0229301</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0229301</pub-id><pub-id pub-id-type="pmid">32084216</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00109"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crosby</surname><given-names>F.L.</given-names></name>
<name><surname>Lundgren</surname><given-names>A.M.</given-names></name>
<name><surname>Hoffman</surname><given-names>C.</given-names></name>
<name><surname>Pascual</surname><given-names>D.W.</given-names></name>
<name><surname>Barbet</surname><given-names>A.F.</given-names></name>
</person-group><article-title>VirB10 Vaccination for Protection against <italic toggle="yes">Anaplasma phagocytophilum</italic></article-title><source>BMC Microbiol.</source><year>2018</year><volume>18</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-018-1346-x</pub-id><pub-id pub-id-type="pmid">30563470</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00109"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Khanzada</surname><given-names>M.H.</given-names></name>
<name><surname>Khan</surname><given-names>K.</given-names></name>
<name><surname>Jalal</surname><given-names>K.</given-names></name>
<name><surname>Uddin</surname><given-names>R.</given-names></name>
</person-group><article-title>Integrating Core Subtractive Proteomics and Reverse Vaccinology for Multi-Epitope Vaccine Design against <italic toggle="yes">Rickettsia prowazekii</italic> Endemic Typhus</article-title><source>Immunol. Res.</source><year>2024</year><volume>72</volume><fpage>82</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s12026-023-09415-y</pub-id><pub-id pub-id-type="pmid">37608125</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00109"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cangussu</surname><given-names>A.S.R.</given-names></name>
<name><surname>Mari&#x000fa;ba</surname><given-names>L.A.M.</given-names></name>
<name><surname>Lalwani</surname><given-names>P.</given-names></name>
<name><surname>Pereira</surname><given-names>K.D.E.S.</given-names></name>
<name><surname>Astolphi-Filho</surname><given-names>S.</given-names></name>
<name><surname>Orlandi</surname><given-names>P.P.</given-names></name>
<name><surname>Epiphanio</surname><given-names>S.</given-names></name>
<name><surname>Viana</surname><given-names>K.F.</given-names></name>
<name><surname>Ribeiro</surname><given-names>M.F.B.</given-names></name>
<name><surname>Silva</surname><given-names>H.M.</given-names></name>
<etal/>
</person-group><article-title>A Hybrid Protein Containing MSP1a Repeats and Omp7, Omp8 and Omp9 Epitopes Protect Immunized BALB/c Mice against Anaplasmosis</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s13567-018-0503-4</pub-id><pub-id pub-id-type="pmid">29351812</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00109"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ganini</surname><given-names>D.</given-names></name>
<name><surname>Leinisch</surname><given-names>F.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Tokar</surname><given-names>E.J.</given-names></name>
<name><surname>Malone</surname><given-names>C.C.</given-names></name>
<name><surname>Petrovich</surname><given-names>R.M.</given-names></name>
<name><surname>Mason</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Fluorescent Proteins Such as EGFP Lead to Catalytic Oxidative Stress in Cells</article-title><source>Redox Biol.</source><year>2017</year><volume>12</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2017.03.002</pub-id><pub-id pub-id-type="pmid">28334681</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00109"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbier</surname><given-names>M.</given-names></name>
<name><surname>Damron</surname><given-names>F.H.</given-names></name>
</person-group><article-title>Rainbow Vectors for Broad-Range Bacterial Fluorescence Labeling</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0146827</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146827</pub-id><pub-id pub-id-type="pmid">26937640</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00109"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winkler</surname><given-names>H.H.</given-names></name>
<name><surname>Wood</surname><given-names>D.O.</given-names></name>
</person-group><article-title>Codon Usage in Selected AT-Rich Bacteria</article-title><source>Biochimie</source><year>1988</year><volume>70</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1016/0300-9084(88)90262-3</pub-id><pub-id pub-id-type="pmid">3147702</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00109"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Rubio</surname><given-names>V.</given-names></name>
<name><surname>Lieberman</surname><given-names>M.W.</given-names></name>
<name><surname>Shi</surname><given-names>Z.-Z.</given-names></name>
</person-group><article-title>OLA1, an Obg-like ATPase, Suppresses Antioxidant Response via Nontranscriptional Mechanisms</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>15356</fpage><lpage>15361</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907213106</pub-id><pub-id pub-id-type="pmid">19706404</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00109"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>M.-Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Miao</surname><given-names>R.</given-names></name>
<name><surname>Fong</surname><given-names>Y.-H.</given-names></name>
<name><surname>Li</surname><given-names>K.-P.</given-names></name>
<name><surname>Yung</surname><given-names>Y.-L.</given-names></name>
<name><surname>Yu</surname><given-names>M.-H.</given-names></name>
<name><surname>Wong</surname><given-names>K.-B.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Lam</surname><given-names>H.-M.</given-names></name>
</person-group><article-title>ATP Binding by the P-Loop NTPase OsYchF1 (an Unconventional G Protein) Contributes to Biotic but Not Abiotic Stress Responses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>2648</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1073/pnas.1522966113</pub-id><pub-id pub-id-type="pmid">26912459</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00109"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.-C.</given-names></name>
<name><surname>Chung</surname><given-names>Y.-T.</given-names></name>
</person-group><article-title>A Conserved GTPase YchF of <italic toggle="yes">Vibrio vulnificus</italic> Is Involved in Macrophage Cytotoxicity, Iron Acquisition, and Mouse Virulence</article-title><source>Int. J. Med. Microbiol.</source><year>2011</year><volume>301</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2011.02.002</pub-id><pub-id pub-id-type="pmid">21570909</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00109"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernebro</surname><given-names>J.</given-names></name>
<name><surname>Blomberg</surname><given-names>C.</given-names></name>
<name><surname>Morfeldt</surname><given-names>E.</given-names></name>
<name><surname>Wolf-Watz</surname><given-names>H.</given-names></name>
<name><surname>Normark</surname><given-names>S.</given-names></name>
<name><surname>Normark</surname><given-names>B.H.</given-names></name>
</person-group><article-title>The Influence of in vitro Fitness Defects on Pneumococcal Ability to Colonize and to Cause Invasive Disease</article-title><source>BMC Microbiol.</source><year>2008</year><volume>8</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-8-65</pub-id><pub-id pub-id-type="pmid">18423011</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00109"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balasingam</surname><given-names>N.</given-names></name>
<name><surname>Brandon</surname><given-names>H.E.</given-names></name>
<name><surname>Ross</surname><given-names>J.A.</given-names></name>
<name><surname>Wieden</surname><given-names>H.-J.</given-names></name>
<name><surname>Thakor</surname><given-names>N.</given-names></name>
</person-group><article-title>Cellular Roles of the Human Obg-like ATPase 1 (HOLA1) and Its YchF Homologs</article-title><source>Biochem. Cell Biol.</source><year>2020</year><volume>98</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1139/bcb-2018-0353</pub-id><pub-id pub-id-type="pmid">30742486</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00109-f001"><label>Figure 1</label><caption><p>Transposon mutagenesis and recombinase-mediated cassette exchange in <italic toggle="yes">Rickettsia parkeri.</italic> (<bold>A</bold>,<bold>B</bold>) pLoxHimar plasmids designed for transposon mutagenesis of rickettsiae with (<bold>A</bold>) mCherry and spectinomycin/streptomycin resistance or (<bold>B</bold>) GFPuv and rifampicin resistance. (<bold>C</bold>,<bold>D</bold>) Plasmids for (<bold>C</bold>) recombinase-mediated cassette exchange (RMCE) and (<bold>D</bold>) expression of the Cre recombinase. (<bold>E</bold>) Schematic showing the process of transposon mutagenesis followed by insertion replacement by RMCE.</p></caption><graphic xlink:href="vaccines-13-00109-g001" position="float"/></fig><fig position="float" id="vaccines-13-00109-f002"><label>Figure 2</label><caption><p>Comparison of murine infection with <italic toggle="yes">Rickettsia parkeri</italic> transposon mutants and wild type. (<bold>A</bold>) Details of disrupted genes in <italic toggle="yes">R. parkeri</italic> mutants and weight change in C3H/HeJ mice 7 days post infection (<italic toggle="yes">n</italic> = 2 mice/infection). Insertion site refers to position in <italic toggle="yes">R. parkeri</italic> Tate&#x02019;s Hell genome. (<bold>B</bold>) Tissue load of <italic toggle="yes">R. parkeri</italic> mutants and wild type at day 7 as determined by qPCR quantification of <italic toggle="yes">gltA.</italic></p></caption><graphic xlink:href="vaccines-13-00109-g002" position="float"/></fig><fig position="float" id="vaccines-13-00109-f003"><label>Figure 3</label><caption><p>Expression of epitope arrays in <italic toggle="yes">Escherichia coli.</italic> (<bold>A</bold>) Diagram showing arrangement and expected molecular mass of different epitope arrays. (<bold>B</bold>,<bold>C</bold>) Expression of epitope arrays in <italic toggle="yes">E. coli</italic> BL21(DE3). Extracts from induced and uninduced cultures were separated by SDS-PAGE and stained with Coomassie (<bold>B</bold>) or probed with anti-6HisTag-HRP conjugate (<bold>C</bold>). 1. YchF uninduced; 2. YchF induced; 3. YchF-Asp55-Asp62-virB9 uninduced; 4. YchF-Asp55-Asp62-virB9 induced; 5. YchF-virB9 uninduced; 6. YchFvirB9 induced; 7. YchF-Asp55 uninduced; 8. YchF-Asp55 induced; 9. YchF-Asp62 uninduced; 10. YchF-Asp62 induced; 11. Untransformed BL21(DE3) control. Asterisks mark the expected band size for each array.</p></caption><graphic xlink:href="vaccines-13-00109-g003" position="float"/></fig><fig position="float" id="vaccines-13-00109-f004"><label>Figure 4</label><caption><p>Challenge of epitope-immunized C3H/HeJ mice with <italic toggle="yes">A. phagocytophilum</italic> or <italic toggle="yes">R. parkeri.</italic> Mice (2 per group) were immunized with purified epitope protein produced in <italic toggle="yes">E. coli.</italic> Two injections of 50 &#x003bc;g were given 4 weeks apart, and pathogen challenge was performed 19 days after the booster dose. (<bold>A</bold>) Average weights of each mouse group following challenge with <italic toggle="yes">A. phagocytophilum</italic> (groups 1&#x02013;5) or <italic toggle="yes">R. parkeri</italic> (group 6). (<bold>B</bold>,<bold>C</bold>) qPCR quantification of <italic toggle="yes">A. phagocytophilum</italic> (<bold>B</bold>) and <italic toggle="yes">R. parkeri</italic> (<bold>C</bold>) in tissues of challenged mice on day 8 post infection. Means were compared using a two-way ANOVA with Dunnett&#x02019;s multiple comparisons test, * indicates <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="vaccines-13-00109-g004" position="float"/></fig><fig position="float" id="vaccines-13-00109-f005"><label>Figure 5</label><caption><p>Detection of mKate-epitope fusion proteins expressed from pRAM18dSGK shuttle vectors in transformed WT <italic toggle="yes">R. parkeri</italic>. (<bold>A</bold>&#x02013;<bold>C</bold>) Western blots of protein extracted from <italic toggle="yes">R. parkeri</italic> transformed with various iterations of epitope cassettes in pRAM18 shuttle vectors. Promoter OmpA or OmpB is shown above the constructs in A and B, whilst all transformants in C used the OmpA promoter. Western blotting against GFPuv confirmed successful transformation with shuttle vectors (<bold>A</bold>). mKate expression was detected in <italic toggle="yes">R. parkeri</italic> transformed with plasmids containing [virB9-mKate] and [Asp62-mKate], but not [Asp55-Asp62-virB9-mKate] or [Asp62-virB9-mKate] (<bold>B</bold>,<bold>C</bold>). Asterisks mark the expected size of mKate-epitope fusion proteins. Numbers on left of blots indicate protein size in kDa; expected size of GFPuv is 27 kDa, virB9-mKate and Asp62-mKate 33 kDa, Asp62-virB9-mKate 37 kDa, and Asp55-Asp62-virB9-mKate 46 kDa. In (<bold>C</bold>) P = pellet and S = supernatant, and the positive control is <italic toggle="yes">R. parkeri</italic> expressing mKate only from pRAM18dSFA. (<bold>D</bold>,<bold>E</bold>) Fluorescent microscopy of <italic toggle="yes">R. parkeri</italic>-infected ISE6 cells gave similar results with mKate visible in pRAM18dSGK[OmpA-virB9-mKate]-transformed rickettsiae (<bold>D</bold>) but not in those transformed with pRAM18dSGK[OmpA-Asp55-Asp62-virB9-mKate] (<bold>E</bold>).</p></caption><graphic xlink:href="vaccines-13-00109-g005" position="float"/></fig><fig position="float" id="vaccines-13-00109-f006"><label>Figure 6</label><caption><p>Detection of mKate-epitope fusion proteins in the <italic toggle="yes">R. parkeri</italic> G8::lox mutant. (<bold>A</bold>) Schematic showing recombinase-mediated cassette exchange in the G8::lox mutant. RMCE results in the replacement of the GFPuv/rif intragenic transposon insertion in RPATATE_1142 with a cassette containing the epitope, mKate, and spectinomycin/streptomycin (&#x0201c;Spec&#x0201d;) resistance sequences. Unlabeled red arrows indicate location of promoters (see <xref rid="vaccines-13-00109-f001" ref-type="fig">Figure 1</xref>). (<bold>B</bold>) Western blot detection of GFPuv and mKate in G8::lox mutants transformed with pRAM18dSGK shuttle vectors containing mKate and epitope sequences and in G8::lox mutants that have undergone RMCE to replace GFPuv/rif transposon with mKate-epitope sequence. Abbreviations used for epitopes: A55 = Asp55; A62 = Asp62; vB9 = virB9. Asterisks mark the expected size of mKate-epitope fusion proteins. (<bold>C</bold>) RT-PCR of DNA/RNA extracts from <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] with primers to virB9 and virB9-mKate. NTC = no template control; noRT = control without reverse transcriptase added; RNA = RNA with reverse transcriptase; DNA = positive control using DNA. (<bold>D</bold>&#x02013;<bold>F</bold>) Fluorescent microscopy of ISE6 cells infected with <italic toggle="yes">R. parkeri</italic> G8::lox expressing GFPuv and mKate from pRAM18dSGK plasmid. mKate-epitope fusion protein was expressed in rickettsiae transformed with plasmids containing virB9-mKate (<bold>D</bold>) and Asp62-mKate (<bold>E</bold>) sequences but not in those containing Asp55-mKate sequences (<bold>F</bold>). (<bold>G</bold>) Fluorescent microscopy of <italic toggle="yes">R. parkeri</italic> G8::lox mutant after RMCE, showing replacement of GFPuv-containing insertion with virB9-mKate cassette.</p></caption><graphic xlink:href="vaccines-13-00109-g006" position="float"/></fig><fig position="float" id="vaccines-13-00109-f007"><label>Figure 7</label><caption><p>Outline of mouse vaccination-challenge experiment.</p></caption><graphic xlink:href="vaccines-13-00109-g007" position="float"/></fig><fig position="float" id="vaccines-13-00109-f008"><label>Figure 8</label><caption><p>Mouse responses to pathogen challenge following vaccination with <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate]. (<bold>A</bold>,<bold>B</bold>) Weights of C3H/HeJ mice challenged with (<bold>A</bold>) <italic toggle="yes">R. parkeri</italic> or (<bold>B</bold>) <italic toggle="yes">A. phagocytophilum</italic>. (<bold>C</bold>) Spleen weights of challenged mice. Means were compared using a one-way ANOVA with Tukey&#x02019;s multiple comparisons test, * indicates <italic toggle="yes">p</italic> &#x0003c; 0.05. Vaccination status is denoted by color (black = unvaccinated control; green = vaccinated; blue = boosted) and pathogen challenge is shown by shape (circle = unchallenged control; triangle = <italic toggle="yes">R. parkeri</italic>; square = <italic toggle="yes">A. phagocytophilum</italic>).</p></caption><graphic xlink:href="vaccines-13-00109-g008" position="float"/></fig><fig position="float" id="vaccines-13-00109-f009"><label>Figure 9</label><caption><p>Tissue load of pathogens in challenged mice vaccinated with <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate]. Copy numbers of (<bold>A</bold>) <italic toggle="yes">R. parkeri</italic> and (<bold>B</bold>) <italic toggle="yes">A. phagocytophilum</italic> in tissues of challenged mice. Means were compared using a one-way ANOVA with Tukey&#x02019;s multiple comparisons test: ns = not significant; * <italic toggle="yes">p</italic> &#x0003c; 0.05; ** <italic toggle="yes">p</italic> &#x0003c; 0.01; **** <italic toggle="yes">p</italic> &#x0003c;0.0001.</p></caption><graphic xlink:href="vaccines-13-00109-g009" position="float"/></fig><fig position="float" id="vaccines-13-00109-f010"><label>Figure 10</label><caption><p>Analysis of response to infection with <italic toggle="yes">A. phagocytophilum</italic> and <italic toggle="yes">R. parkeri</italic> in mice vaccinated with <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate]. (<bold>A</bold>) Giemsa results from blood cultures of <italic toggle="yes">A. phagocytophilum</italic>-challenged mice. Data were analyzed by two-way ANOVA: No significant difference by vaccination status, <italic toggle="yes">p</italic> &#x0003c; 0.0001 by time. (<bold>B</bold>) PER1/2 PCR results from day 11 blood cultures of <italic toggle="yes">A. phagocytophilum</italic>-challenged mice. Expected band size is 451 bp. A, B, and C are individual mice from each group. (<bold>C</bold>) IFA on <italic toggle="yes">R. parkeri</italic>-infected ISE6 cells using sera from unvaccinated, unchallenged mice (negative control), sera taken from mice 3 dpi with WT <italic toggle="yes">R. parkeri</italic> (<italic toggle="yes">Rp</italic>-exposed), and sera from vaccinated and boosted mice (taken on day 35). 40&#x000d7; magnification. (<bold>D</bold>) IFA on <italic toggle="yes">A. phagocytophilum</italic>-infected HL60 cells using sera from unvaccinated, unchallenged mice (negative control), sera taken from mice 7 dpi with WT <italic toggle="yes">A. phagocytophilum</italic> (<italic toggle="yes">Ap</italic>-exposed), and sera from vaccinated and boosted mice (taken on day 35). 40&#x000d7; magnification. (<bold>E</bold>) ELISA against wells coated with <italic toggle="yes">A. phagocytophilum</italic>, WT <italic toggle="yes">R. parkeri</italic>, or <italic toggle="yes">R. parkeri</italic> G8::lox[virB9-mKate] and probed with serum from five groups of mice (listed on x-axis). Well contents are indicated by color of bars. Dotted line represents the positive cut-off value calculated as mean + 3 standard deviations of the negative control. Absorbance was adjusted to a blank well containing no bacteria to which no sera were added.</p></caption><graphic xlink:href="vaccines-13-00109-g010" position="float"/></fig><table-wrap position="float" id="vaccines-13-00109-t001"><object-id pub-id-type="pii">vaccines-13-00109-t001_Table 1</object-id><label>Table 1</label><caption><p>Epitopes selected based on predicted characteristics of immunogenicity, surface accessibility, beta-turn presence, and hydrophilicity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amino Acid Residues</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Predicted Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amino Acid Sequence</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asp55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">467&#x02013;528</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">antigenic, surface, hydrophilic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDGENTLKDLVVGVGYNLFSKGSTSLEVFLNCHMFSVQHKFNIHEYKVSTESKVSTESKVYT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asp62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111&#x02013;148</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">antigenic, beta-turn</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EYLSDSGTAYGADFQVMVPEVNSAVEVGKAFINRGSRA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">virB9-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98&#x02013;145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">antigenic, beta-turn</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EKEGHTNMLIETSKGRSYAFDLISTAIPLSGGAASSINKLGKTNSALA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YchF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">134&#x02013;221</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">antigenic, surface-accessible</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KVLGEDKPARVLNEALRVDNLKQLQLITSKPVLYICNVLEKDAAIGNEFTK</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00109-t002"><object-id pub-id-type="pii">vaccines-13-00109-t002_Table 2</object-id><label>Table 2</label><caption><p>List of constructed epitope arrays.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Construct</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Successfully Transformed into <italic toggle="yes">R. parkeri</italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression Confirmed by RT-PCR</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr promoter-[YchF-Asp55-Asp62-VirB9]-6His Tag</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">partly</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr Promoter-[YchF]-6His Tag</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr Promoter-[YchF-Asp62]-6His Tag</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr Promoter-[YchF-Asp55]-6His Tag</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr Promoter-[YchF-VirB9]-6His Tag</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Amtr Promoter-[Asp55-Asp62-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amtr promoter-[VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[YchF-Asp55-Asp62-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[YchF]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[YchF-Asp62]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[YchF-Asp55]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[YchF-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-Asp62-VirB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[VirB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-Asp62-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OmpA Promoter-[VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[Asp55-Asp62-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[YchF-Asp55-Asp62-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[YchF]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[YchF-Asp62]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpB Promoter-[YchF-Asp55]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OmpB Promoter-[YchF-VirB9]-6His Tag-OmpA terminator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[virB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-Asp62-VirB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-virB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp55-Asp62-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Partly</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp62-virB9-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Partly</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-[Asp62-mKate]-6His Tag-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OmpA Promoter-6His Tag-[Asp62-mKate]-OmpA terminator</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OmpA Promoter-[Asp62-mKate]-8His Tag-OmpA terminator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr></tbody></table></table-wrap></floats-group></article>